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Abstract:  
    There are a variety of plants that have been recognized and used in traditional medicine for 
their health benefits. Among these plants is Andrographis paniculata, commonly known as the 
king of bitters because of its bitter taste. In the past, Andrographis paniculata has been used to 
treat various ailments, including respiratory infections, the common cold, snake bites, 
inflammation and diarrhea. We have tested the effect of Andrographis paniculata extracts on the 
growth of malignant cancer cells and its potential benefits towards cancer treatment. Cancer 
cells, including B16- BL6, MCF-7, MDA-MB-231, 4T1, and ASPC-1 cells, were treated with 
70% ethanol extracts or aqueous extracts of Andrographis paniculata with a range in 
concentration from 0.1 to 1%. Treatment with the ethanol extract of Andrographis paniculata 
inhibited cell growth when added at 0.25% to 1%. The aqueous extract was less potent and 
inhibited cell growth at only 1%. Treatment of B16- BL6 cells with 1% of the aqueous extract of 
Andrographis paniculata for 48 h induced apoptosis as detected using the acridine orange/ 
ethidium bromide cell staining assay. On the other hand, treatment with the ethanol extract had a 
much stronger effect and cell staining showed late stage apoptosis and loss of membrane 
integrity. We have shown that treatment of B16- BL6 cells with Andrographis paniculata 
extracts altered cell survival pathways and promoted apoptosis by using western blot analysis for 
ERK ½, phosphorylated-ERK and Caspase 3. Similarly, the treatment of B16-BL6 with the 
ethanol extract for 48 h increased the number of cells in the Sub-G1 phase, in comparison to 
treatment with the aqueous extract, by using flow cytometry of propidium iodide-stained cells. 
Overall, this study demonstrated that Andrographis paniculata had successfully suppressed the 
growth of malignant cancer cells.   
Keywords: Andrographis paniculata, Malignant cancer cells, Apoptosis, Caspase 3, Sub-G1.  
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Chapter 1: Introduction  
1.1 Cancer as a Problem  
       Cancer comprises of over two hundred diseases that have similar characteristics. One 
common characteristic of these diseases is that they are marked by uncontrolled multiplication 
and growth of cells (Edmunds, 2007; Gabriel, 2007). Cancer is a top cause of death in the United 
States and in parts of Europe, ranking second behind cardiovascular disease (Ruddon, 2007). In  
2016, approximately 1.7 million new cancer diagnosis and 600,000 deaths are expected in the 
United States, according to the American Cancer Society estimates. Exposures to environmental 
carcinogenic agents and lifestyle factors are thought to account for differences in geographical 
rates of cancer incidence. Some of these lifestyle factors include diets with high fat, calories and 
red meat (Pardee et al., 2009).   
       Any cell has a chance of becoming malignant (cancerous) when there is disruption or failure 
of the standard cell control mechanisms (Gabriel, 2007). Cancer development is a consequence 
of a destabilization in the balance between cell division, differentiation and death. When there is 
uncontrolled division, a tumor resulting from the growth of abnormal cells can result and these 
growths become cancer if they have the ability to invade neighboring tissues (Lambert et al., 
2009). In addition to abnormal division, malignant cells can result from an accumulation of gene 
mutations and tumors can appear 20 years or more after the first mutations that initiated the 
cancer. Mutation hampers the ability for cell differentiation and facilitates the spread to other 
locations (Pardee et al., 2009).   
      Treatment of patients with cancer is usually through the surgical removal of the tumor. 
However, this is not always successful because of the microscopic spread of cancer cells to 
surrounding tissues which may be undetected or appear noncancerous to the surgeon. If left 
untreated, the cancers can then re-emerge and spread. Replication of malignant cells leads to 
2  
  
infiltration of the surrounding tissues including blood vessels and lymphatics thus enabling them 
to be carried to other parts of the body where they can continue the process of growth and 
replication (Gabriel, 2007). Cancer cells can mutate in ways that enable them to evade the 
surveillance of the immune system. For example, some cancer cells can secrete transforming 
growth factor-beta, a cytokine that interferes with anti-cancer immune system cell function 
(Pienta, 2009). Consequently, the cancer cells can relentlessly, colonize other locations and 
present an enormous challenge in treatment (Eleni & Christopher, 2009).  
  
     
3  
  
  
 
  
                     Malignant melanoma (skin cancer) stages (National cancer institute., 2016).                        
                                   https://www.cancer.gov/types/skin/patient/melanoma-treatment-pdq#section/_96  
  
  
  
                         Breast cancer stages (https://en.wikipedia.org/wiki/Breast_cancer).  
  
          
  
                          Pancreatic cancer stages (https://en.wikipedia.org/wiki/Pancreatic_cancer  
                                                 Cancer as a Problem   
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1.2. Malignant Melanoma  
        Melanoma is one of the cancers that shows an increasing rate of incidence and mortality. 
Early detection of the disease contributes to the survival of the patient. The tumor’s thickness has 
been regarded as the most significant factor to affect the patient’s survival. The five-year rate of 
survival for patients is 94% for melanoma thinner than 1mm compared to less than 50% for those 
with a tumor thicker than 3mm. Melanoma is characterized as a tumor with an aggressive 
potential for replication and a high possibility to spread. While excessive exposure to the sun 
remains the primary risk factor, others risks include blistering sunburns, atypical mole syndrome, 
UV light exposure, immune suppression and a history of the condition in a first-degree kin (Rigel 
et al., 2000). The incidence of the disease varies with latitude, increasing in frequency with 
proximity to the equator. Lifestyle changes, characterized by increasing outdoor recreation and 
less skin coverage, also increase incidence. Other risk factors include childhood sunburns, and 
prolonged exposure to fluorescent lighting or to polychlorinated biphenyl compounds (Bailin et 
al., 2002).  
        There are specific patient phenotypes that increase the risk of the disease including blue 
eyes, sun sensitivity, light skin complexion, red hair, and diagnosis of a non-melanoma skin 
cancer (Rigel et al., 2000; Bailin et al., 2002). A multivariate study singled out six factors that 
independently affected the risk of developing the disease. The factors include; a family history of 
the disease, red hair, marked freckling present on the upper back, a history of more than three 
blistering sunburns before 20 years of age, outdoor jobs for three or more years for teenagers, 
and the existence of actinic keratosis (Rigel et al., 2000). Skin prototype is also a risk factor, and 
the condition is predominant among whites, accounting for about 70 % of melanoma cases which 
are largely credited to sun-exposure (Barnhill, 2003).  
5  
  
  
  
  
  
Figure 1.1. The ABCD melanoma guideline for diagnosis (Asymmetry pattern, Border 
irregularity, Color variegation and Diameter)  https://en.wikipedia.org/wiki/Melanoma    
 
 
 
6  
  
      According to Barnhill (2003), the common symptoms for diagnosis of melanoma include a 
change in the color and size of skin lesions, bleeding and ulceration of the lesions, and as the 
cancer advances it becomes itchy. Early recognition of the condition can be done through an 
ABCD guideline (Figure 1) which includes; Asymmetry patterns that result from the uneven 
growth of lesions, which in turn leads to Border irregularity. Such inconsistency causes Color 
variegation forming shades of black and light and dark brown. Lesions that have the ABC 
features coupled with a Diameter that exceeds 6 mm are to be considered suspicious of 
melanoma (Rigel et al., 2000).  
        Because a skin biopsy is a relatively simple procedure, lesions that are suggestive of 
cancerous melanoma should be assessed for early detection. Moreover, self-examination by 
patients also contributes to early detection and seeking a physician's advice if they notice new 
pigmented lesions increases early diagnosis. Surgical excision is the primary and most efficient 
method of treating early tumors. More advanced tumors are also treated with chemotherapy, 
adjuvant therapy, and vaccines (Rigel et al., 2000). The limitations to early treatment include 
delayed medical assessment by patients who have suspicious lesions due to denial, fear or 
because they lack knowledge. The existence of nodal metastases reduces the 5-yr rate of survival 
by at least 40 %. In addition, it is prudent to follow the patients’ condition after diagnosis in 
order to detect recurrences and to continue treatment to enhance long-term survival. 
Unfortunately, recurrent disease is not always treatable and treatment of melanoma is not 
necessarily curative. Although it has not yet been proved experimentally, it is thought that patient 
follow-up and the rate of survival are directly linked. There is a greater risk of recurrence of 
melanoma in the first year following the original diagnosis and treatment, which declines  
steadily over time. Most recurrences are symptomatic, and therefore, self-examination can play a 
crucial role in seeking medical attention (Bailin et al., 2002).  
7  
  
1.3. Breast Cancer  
       According to Afonso (2009), the approaches to identifying women at high risk of developing 
breast cancer include evaluating family history, clinical history records, and assessing 
mammographic density. Further, the study notes that inherited factors account for only 1 to 2% 
of all breast cancer cases. The incidence of breast cancer increases as the individual ages with a 
majority of diagnosis in women after 40 years old. Delayed childbirth has been suggested to be a 
contributing factor for women past 35 years while childbearing is associated with risk for women 
below 35 years.   
         For diagnosis, ultrasound is considered to be more efficient than a mammogram in the 
detection of breast cancer among young women and it can distinguish between solid masses and 
cysts. A breast MRI screening is recommended for women with a 20-25% lifetime risk including 
those with a familial syndrome and those having received chest radiation. Treatment of cancer 
often includes breast conserving surgery coupled with radiation. Surgery as a treatment method 
is determined, by among other things, the preference of the patient, the size of the tumor, prior 
radiation and the likelihood of attaining an acceptable cosmetic outcome. Breast conservation, 
especially among young women, is associated with an increased risk of recurrence compared to 
older women (Gabriel & Domchek, 2010).  
       Chemotherapy as a method of treatment is insufficient on its own, and endocrine therapy 
should be incorporated in the treatment plan. Alternatively, a combination of tamoxifen with 
ovarian suppression could be used in place of other treatments. Chemotherapy can lead to 
permanent menopause and is a concern in the treatment of young women. Additionally, women 
would have to delay pregnancy until after the tamoxifen treatment is completed due to 
teratogenicity. This means a women might have to wait 5 years, which is the optimal duration of 
treatment, before getting pregnant although her fertility decreases as she advances in age. 
8  
  
Pregnancy following early diagnosis has no negative influence on the rate of patient survival. For 
women who prefer to bear children after treatment, there is a need for fertility procedures to be 
commenced before therapy since treatment is likely to cause genetic damage to oocytes. 
Therefore, such patients should be referred to a fertility specialist before systematic therapy is 
initiated.  Such fertility measures include ovarian preservation, embryo cryopreservation or 
oocyte cryopreservation (Gabriel & Domchek, 2010).  
       To prevent recurrence, women with a history of the disease should have annual mammogram 
screening. Maintaining a healthy weight and physical activity reduces the risk of recurrence. 
Deficiency in vitamin D has been identified as a contributor to recurrence and death in patients 
diagnosed with an early stage of the disease. Diagnosis can be distressing for women.  Those 
who experience treatment-induced menopause have lower health perspectives compared to their 
peers. The situation has been interpreted to imply that diagnosis at a young age comes with an 
emotional shock and physical demands which make it more difficult to endure treatment. 
Furthermore, concerns about fertility loss, sexual dysfunction and deteriorating body image for 
women who undergo mastectomy increases the emotional strain on survivors. Thus, early 
counseling and support needs to be incorporated into the management of these patients (Gabriel 
& Domchek, 2010).       
  
9  
  
  
Figure 1.2. Breast cancer was detected by mammography in the right breast compared to 
the normal breast in the left side.     https://en.wikipedia.org/wiki/Breast_cancer  
  
  
       Estrogen receptor (ER) is a key focus in breast cancer treatment and prevention. The risk of 
estrogen-dependent breast cancer can be minimized through exercise and reduction in body 
weight, cessation of alcohol intake among postmenopausal women and increased dietary folate 
(Afonso, 2009). Menopausal hormones are thought to be a cause of breast cancer. Moreover, the 
association between estrogen and breast cancer implies that assessment needs to be done before 
counseling women on methods of relieving menopausal symptoms to ensure that the choices do 
not increase their susceptibility to chronic diseases (Colditz, 1998).  
1.3.1. ER Positive Breast Cancer & HER2 positive breast cancer:  
        Patients with ER-positive tumors are more common than patients with ER-negative ones 
across all ages and the incidence of positivity increases with age. Consequently, breast cancers in 
women of postmenopausal age are mostly ER positive. ER positive tumors are more likely to be 
smaller, low-grade and lymph node negative. The type is more prevalent among Caucasian 
10  
  
women and recurs at a low, steady rate. The estimated long-term recurrence is about 2% per 
annum. Moreover, a diagnosis of ER-positive breast cancer is associated with better prognosis 
except for black women diagnosed with ER positive and HER2 negative breast cancer. Patients 
with ER positive tumors who have partial irradiation have a reduced chance of experiencing 
recurrence.   
         In HER2 positive breast cancer; the oncogene HER2 is overexpressed. The type accounts 
for about 20 percent of breast cancers. HER2 positive breast cancer has a high likelihood of 
manifesting itself symptomatically. These tumors are more prevalent among the young and have 
more lymph node involvement. The median survival for patients with advanced HER2 positive 
breast cancer is over two years. If treatment involves conserving surgery, recurrences are more 
common for this type than any other type, such as ER+ and HER2- due to residual disease at re-
excision (Cadoo, Fornier & Morris, 2013).    
1.3.2. Triple negative breast cancer (TNBCs):  
        This type of tumor does not express the ER, PR or HER-2 genes. The main treatment for 
patients with triple negative breast cancer includes chemotherapy, and recent developments 
includes the application of EGFR inhibitors as a therapeutic option although with mixed results 
(Hudis & Gianni, 2011). Although the triple-negative subtype accounts for a minority of breast 
cancer cases, it has a disproportionately higher number of deaths. Since the triple-negative type 
consists of tumors that do not have targeted therapeutics, clinicians exclusively rely on 
nonspecific cytotoxic agents (Schneider et al., 2008). Cytotoxic chemotherapy is the standard 
mode of care. The subgroup accounts for about 15% of all breast cancer incidences with 
prevalence being highest among African-Americans, young women, and patients with mutations 
in the BRCA1/BRCA2 genes. The type manifests with an aggressive phenotype and poor 
prognosis. Triple negative breast cancers are unlikely to have any involvement of lymph nodes. 
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Patients diagnosed with triple negative breast cancer in the early stages, with no incidences of 
tumor relapse in the first five years after treatment have a high likelihood of being cured. 
However, patients with triple negative breast cancer have a higher risk to develop metastases 
during the first five years following diagnosis. Further, there is a significant risk of both CNS 
and pulmonary involvement as sites of recurrent disease while bone involvement is less likely 
(Cadoo, Fornier & Morris, 2013).  
  
1.4. Pancreatic Cancer  
         The American Cancer Society predicts that in 2016, pancreatic cancer will kill 
approximately 41,780 people (20,330 women and 21,450 men). The reason for the high rate of 
mortality is because less than 20% of patients have localized, more easily treated tumors, when 
they are diagnosed (Hidalgo, 2010). A major problem is that patients with pancreatic tumors do 
not show symptoms until the tumors are very advanced and therefore diagnosis is usually very 
late in cancer progression. The contributing factors for risk of pancreatic cancer are smoking, 
male gender, African-American ethnicity, diabetes mellitus, history of chronic pancreatitis in the 
family, obesity, advanced age, and non-O blood group (Vincent et al. 2011). Twenty percent of 
tumors result from cigarette smoking and tumors in smokers have higher mutation rates than 
those from non-smokers. Also, family history accounts for between 7 and 10 % of the disease 
incidence with the first-degree relatives of a person's familial type having a nine times more risk 
compared to the general populace. For kindreds with at least three first-degree relatives of the 
disease, the risk is increased 32-fold (Vincent et al. 2011).   
       In patients with a strong family history of pancreatic cancer, identification of the 
predisposing gene could allow for testing screening, and chemoprevention in identified relatives. 
Genetic testing for pancreatic cancer is underutilized because there is the lack of recognition of 
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the family history and secondly because there is usually inadequate recording of family history 
(Vincent et al. 2011). For most patients diagnosed with pancreatic cancer, life expectancy is a 
matter of months. High morbidity results from the fact that the cancer disseminates to distant 
sites early and is resistant to most currently available treatments (Li et al., 2004).         Diagnosis 
of patients for pancreatic cancer should be performed using a CT scan and endoscopic 
ultrasonography. The disease's manifestations are vague and nonspecific and lead to a delay in 
diagnosis. When it presents, it may be in the form of weight loss, jaundice and abdominal pain 
(Zhang et al., 2016). Various options for diagnosis exist where pain without jaundice is 
experienced, but a CT scan remains critical for observing pathology within the pancreas. 
Symptoms of tumors in the pancreas result from compression of surrounding organs including 
the bile duct, duodenum and nerves and these effects imply that diagnosis can be made rather 
quickly. The main symptoms include back and abdominal pain, diabetes mellitus, and 
obstructive jaundice (Li et al., 2004).  
       For cases of locally advanced disease with the tumor encasing a vascular structure but with 
no proof of distant metastatic disease in the liver, peritoneum, and chest, the conventional 
treatment is fluorouracil-based chemotherapy and radiation (Li et al., 2004). In patients with 
metastatic disease, survival depends on the situation and the burden exerted by the tumor. 
Chemotherapy at this stage is palliative rather than curative, and its impacts on quality of life 
need to be considered in contrast to the toxic effects (Li et al., 2004). Over 80 % of patients with 
pancreatic cancer have unrespectable tumors because the disease has metastasized. The use of 
chemotherapeutic agents on patients with advanced disease results in a 5-year survival rate of 
1015% (Nunes & Lobo, 2007).  
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1.5. Cancer Treatment  
     The options for cancer treatment recommended by a doctor depend on the type as well as the 
stage of the disease, probable side effects, and the patient’s overall health. Once a tumor has 
been identified, various options can be pursued to treat the cancer. These options include 
surgery, radiotherapy, hormonal therapy, and stem cell transplants, among others. The options 
can be used to cure cancer as well as to provide palliative care to cancer patients by alleviating 
the symptoms of the disease (Canadian Cancer Society, 2016).  
1.5.1. Chemotherapy:  
       Chemotherapy is the utilization of cytotoxic medicine to kill cancer cells which most 
commonly targets fast growing cells by disrupting DNA replication or cell division and causing 
cell death. However, since the chemotherapy drugs are powerful, they can lead to damage of any 
growing cells, including healthy ones such as blood cells, immune cells, and fast reproducing 
cells in the gastrointestinal tract. As such, the damage causes many side effects (Healthline 
Media, 2016). Briefly, some of the short-term side effects include fatigue, pain (stomach ache, 
headache, and muscle pain), throat and mouth sores, diarrhea, vomiting, and nausea, 
constipation, blood disorders, nervous system effects, changes in memory and thinking, 
reproductive and sexual issues, loss of appetite, and hair loss. Nonetheless, most effects 
disappear after treatment although some can last for months after chemotherapy ends (Healthline 
Media, 2016). In addition, some kinds of chemotherapy may lead to permanent damage of the 
reproductive system, kidneys, liver, lungs, and heart. Moreover, some individuals develop 
problems in concentrating, memory, and thinking that can persist for months or years after 
treatment (University of Rochester Medical Center Rochester, 2016).  
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1.5.2. Radiotherapy:  
        Radiotherapy is employed as a primary cancer treatment, and it is often given after surgery 
to eliminate any residual cancer cells (Schulz, 2005). The process can be conducted either 
externally or internally. External radiation with high energy, such as from x-rays, electron beams 
and gamma rays have adequate energy to significantly damage cells. When it happens, it can 
result in enough damage to ultimately destroy the cells. Thus, its critical goal is to obliterate the 
cancer cells, which slow down tumor growth, but to avoid damaging nearby healthy tissues 
(American Cancer Society, 2016). One of the main research aims of radiation therapy is to 
improve targeting of the tumors to create the least amount of damage to neighboring tissues. 
However, similar to other treatment options, this method also causes a variety of side effects 
depending on the type of cancer, general health, location, and dose. Some of the common short-
term side effects include skin problems and fatigue. However, even though some of the effects 
may disappear after treatment, some may progress for months after treatment ends (National 
Cancer Institute, 2016; American Cancer Society, 2016).  For example, exposure to radiotherapy 
is also a risk factor for new cancers.  
1.5.3. Surgery:  
        The major goal of surgery is the physical removal of the tumor as well as a small amount of 
surrounding tissue (the tumor margin) during an operation. The goals of surgery vary as it can 
also be utilized at the diagnostic stage, where a sample of tissue is removed from the patient's 
body and examined for any traces of cancer (biopsy). Accordingly, the surgical removal of the 
tumor may be the only treatment, or it may be combined with chemotherapy or radiotherapy, or 
other alternatives that may be available before or after surgery. Similar to other treatment 
options, this method also has its side effects that may include pain, fatigue, limb swelling, 
bleeding, infection and organ dysfunction (Canadian Cancer Society, 2016).  
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1.6. Natural products as anti-cancer agents  
       The rapid expansion of synthetic protein kinase inhibitors and monoclonal antibodies against 
cancer targets for the treatment of cancer in the late 1990s led to anticancer natural products 
being disregarded by the pharmaceutical industries (Bailly, 2009). However, in 2007 three new 
drugs developed from natural products were approved for clinical use signaling the re-emergence 
of promising antitumor compounds derived from microorganisms, and the increasing 
significance of novel formulations of recognized natural product-derived medicines, resulting in 
a new wave of natural products in oncology (Bailly, 2009). Further, there is a clear indication 
that the escalating use of microbial sources has increased the discovery of medically helpful 
natural products (Bailly, 2009).   
        Natural products have been an irresistible success in society. They have long been used to 
minimize pain and suffering in addition to revolutionizing medicine by facilitating organ 
transplantation. Natural products have been the source of most of the currently used essential 
anti-inflammatory and anticancer agents. Accordingly, over 60% of approved drugs and new 
drug application candidates are either natural products or are derived from them (excluding 
biologicals, such as monoclonal antibodies and vaccines) (Cargg et al., 1997; Demain & Zhang, 
2005). Many natural products are used as chemoprotective agents against numerous common 
cancers worldwide. Correspondingly, a primary collection of such products include powerful 
antioxidants, others are phenolic in nature, and some have specific reactive groups, which can 
confer protective properties. The natural products have been most frequently found in studies 
looking at herbs, plant extracts, fruits, and vegetables. Even though the mechanisms of action for 
many of these agents are not clear, the idea that the use of vegetables and fruits reduces the 
incidence of carcinogenesis is widely supported (Reddy et al., 2003).  
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         Natural products for anticancer agents are derived from divergent natural sources. For 
example, one of the most notable examples of an anticancer agent isolated from plants is the 
vinca alkaloid family (e.g. Vinblastine) isolated from the Periwinkle Catharanthus roseus found 
in the Amazon rain forest (Noble.,1990). Another excellent example is etoposide, derived from a 
microbe, that has led to high rates of cure in testicular cancer when utilized together with 
bleomycin and cisplatin that are derived from natural products as well (Da Rocha et al., 2001; 
Williams et al., 1987). Moreover, marine sources have also been significant sources of anticancer 
agents. Other sources include marine organisms, soft corals, sponges, seaweeds, and marine 
invertebrates (Mann, 2002; Faulkner, 2000; Faulkner,2001). Many ecteinascidins have been 
isolated from the marine tunicate Ecteinascidia turbinate. According to pre-clinical research, one 
of the ecteinascidins (ET-743) is toxic to many tumor cell lines in nanomolar to subnanomolar 
concentrations (Da Rocha et al., 2001; Rinehart, 2000).  Andrographis paniculata has also been 
found to be a useful plant having medicinal properties and anti-cancer compounds. Such plants 
are believed to possess defensive mechanisms, including toxins that act against parasites and 
insects, which can be used to prevent and treat human cancer (Da Rocha et al., 2001).   
         The introduction of the natural active agents into the cancer armamentarium has changed 
the natural history of most kinds of human cancer. Experimental agents from natural products are 
offering a significant chance to discover not only entirely new anticancer agents’ chemical 
classes but also new and potentially relevant mechanisms of action (Da Rocha et al., 2001).          
In addition, the incidence of cancer can be substantially minimized by changing diets. A diet rich 
in legumes, vegetables, and fruits which has an immense amounts of antioxidants, can protect 
against the harmful activity of free radicals that may promote the development of cancer. It has 
also been illustrated that while synthetic cancer medicines often lead to the non-specific 
destruction of cells, natural products may contain more selective agents and may have reduced 
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cytotoxicity for noncancerous cells and may be able to promote nutrient repletion in 
compromised individuals (Reddy et al., 2003).  
  
1.7. Andrographis Paniculata  
          Andrographis paniculata, commonly referred to as the “king of the bitters”, is a 
herbaceous plant belonging to the Acanthacease family (Jayakumar et al., 2013). It is mainly 
found throughout subtropical and tropical India, Southeast Asia, and Asia. Moreover, its extracts, 
alongside purified Andrographolide, show pharmacological activities that are 
immunostimulatory (Kumar et al., 2004), antibacterial (Singha et al., 2003), and antiviral 
(Calabrese et al., 2000; Jayakumar et al., 2013). In traditional medicine, Andrographolide is 
broadly utilized to reduce body heat, dispel toxins from the body, avert the common cold and 
infections of the upper respiratory tract (Gabrielian et al., 2002), and as a snake and insect poison 
antidote (Samy et al., 2008; Joselin & Jeeva, 2014). Additionally, it has been suggested to have 
potential therapeutic action in treating colds, frequent coughs, and liver disorders in humans 
(Geethangili et al., 2008). The distinctive secondary metabolites made by the plant have 
significant value in the area of medicinal plants (Joselin & Jeeva, 2014).  
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                         Figure 1.3. Andrographis paniculata morphology (Jayakumar et al., 2013)  
                                       https://www.hindawi.com/journals/ecam/2013/846740/  
  
        Andrographis paniculata is an annual, branched, herbaceous plant rising to a height of 30 to 
100 cm in humid dark areas (Joselin & Jeeva, 2014). Moreover, the stem is quadrangular; much 
branched, and is easy to break due to its brittle texture. Its leaves are simple, glabrous, 
lanceolate, 2 to 12 cm long and 1 to 3cm broad with an entire sharp margin (Joselin & Jeeva, 
2014). In addition, inflorescence is axillary and terminal in panicle, 10 to 30 mm long, with a 
short pedicel and small bract (Joselin & Jeeva, 2014). The flowers have calyx with five sepals 
that are linear and small. The corolla tubes are narrow, approximately 6 mm long, the upper lip 
oblong, bilabiate, and white with a yellowish top while the lower tips are widely cuneate, 3 
lobed, and white with violet markings (Joselin & Jeeva, 2014).  
        The aerial part of the plant has been commonly utilized for its medicinal value. Nonetheless, 
the whole plant, including the roots, is mentioned for particular limited usages in some 
manuscripts (Akbar, 2011). Traditionally, it was used as a decoction, powder, or an infusion, 
either in combination with other medicinal drugs or alone. However, in contemporary times, the 
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commercial preparations used in controlled clinical tests have tended to be standardized extracts 
of the entire plant (Akbar, 2011).   
  
                                                  
              Figure 1.4. The chemical structure of andrographolide (Jayakumar et al., 2013)  
                                 https://www.hindawi.com/journals/ecam/2013/846740/   
                                         https://en.wikipedia.org/wiki/Andrographolide  
  
         Andrographolide is a key bioactive phytoconstituent of Andrographis paniculata and is 
found in various parts of the plant but mostly in the leaves (Chao & Lin, 2010).  
Andrographolide, has been found to treat variety of diseases including melanoma, lung cancer, 
leukemia and breast cancer (Jayakumar et al., 2013; Nanduri et al., 2004; Rajagopal et al., 2003).               
Andrographis paniculata has numerous pharmacological properties. Recent research has 
suggested that it has some immunological potential in that the extract may be capable of 
interfering with the viability of HIV.  It is also a candidate therapeutic anticancer pharmacophore 
which has dual properties, acting both indirectly and directly on cancer cells (Jarukamjorn & 
Nemoto, 2008). The methanolic extract of the plant has shown toxicity against lymphocytic and 
human epidermoid leukemia cell lines (Siripong et al., 1992). Different studies have indicated 
that andrographolide efficiently induces cell-cycle arrest at the G0/G1 checkpoint in cancer cells  
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(Geethangili et al, 2008).  
       Furthermore, extracts containing andrographolide are recognized to have an anti-
inflammatory potential (Chiou et al., 1998; Chiou et al., 2000). Plant extracts were also found to 
inhibit the proliferation of Plasmodium berghei, one of the insects known to transmit malaria 
(Misra et al., 1992). It was also established that Andrographis paniculata extracts can cause 
pregnancy termination, and has anti-fertility effects (Kamal et al., 2003; Deshpande et al., 2014).  
1.7.1. Safety and Dosage of Andrographis Paniculata  
        Andrographis paniculata has been shown to be safe in conventional Chinese medicine. 
Even though human trial and error may not be regarded scientific, it is a method of establishing 
whether a substance is harmful or useful. Apparently, when the safety of the plant was under 
scrutiny from scientists, formal toxicological research in animal models alongside human clinical 
tests substantiated that andrographolide together with the other constitutes had exceedingly low 
toxicity (Joselin &Jeeva, 2014).  
        According to an antifertility test conducted on rats administered with Andrographis 
paniculata, no toxicity was found even at a high dose.  The LD50 of andrographolide in male 
mice administered through the intraperitoneal route was recorded to be 11.46 g/kg (Handa & 
Sharma., 1990; Jayakumar et al, 2013). Further, in research carried out on HIV-positive 
individuals, a dose of 1,500 to 2,000 mg andrographolide was administered on a daily basis for 
six weeks (Jayakumar et al., 2013). The study was concluded early in spite of some 
enhancements in the count of CD4 and the observation that the side effects were ordinary 
(Calabrese et al., 2000). Additionally, 10 mg/kg of andrographolide was administered to rabbits, 
and did not result in changes to the liver, heart, spleen, and kidney (Guo et al., 1988). Moreover, 
administering andrographolide does not cause cytotoxic impacts to platelets at concentrations 
between 35 and 150 mM (Lu et al., 2011; Jayakumar et al., 2013). Additionally, research also 
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indicates that pre-treatment with Andrographis paniculata and andrographolide at 500 mg/kg 
body weight and 125 mg/kg body weight, respectively, could reduce toxicity (Singha et al., 
2007; Jayakumar, et al., 2013).   
     However, similar to all herbs, some people can have an allergic reaction to Andrographis 
paniculata.  Nevertheless, the present evidence has shown andrographolide is a naturally 
occurring compound that has minimal toxicity. Accordingly, it is suggested that it should be 
clinically tried as a pharmaceutical agent and that using it for health promotion or as an 
alternative medical therapy should be done cautiously (Jarukamjorn & Nemoto, 2008;  
Jayakumar, et al., 2013).                                     
1.7.2. Anticancer activities of Andrographis paniculata  
         Andrographis paniculata has a wide variety of uses in traditional medicine in several 
countries of Southeastern Asia (Lin et al., 2013). The main components of this herb are diterpene 
lactones, with about 70% of the extract being made up of andrographolide, which has several 
pharmacological properties and is widely used for the clinical treatment of inflammation, fever, 
diabetes, cold, diarrhea, among other infectious ailments (Lin et al., 2013). Findings from studies 
carried out recently suggest that extracts of Andrographis paniculata have anticancer as well as 
immunoregulatory activities (Lin et al., 2013). It can potentially be applied during 
chemotherapeutic management of various medical conditions (Lin et al., 2013). Despite the wide 
applications of andrographolide in the traditional management of various conditions, the precise 
mechanisms involved in its actions are still vague (Shen et al., 2013). This chapter presents a 
review of several publications reporting findings on the mechanisms of action involved in the 
anticancer activities displayed by extracts from Andrographis paniculata.  
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1.7.3. Human Colorectal Carcinoma:  
         In their publication, Lin et al, (2013) present the issue of colorectal cancer, which is among 
the leading causes of death due to cancer around the globe. When discovered in its early stages, 
this cancer may be cured by surgical procedures. However, in advanced stages, it often causes 
death due to recurrence, even among patients treated with combination chemotherapy. 
Oxaliplatin, CDDP (cisplatin), and other platinum drugs are key chemotherapy agents utilized 
against various cancers including colorectal, cervical, lung, and testicular cancers, and are 
particularly important in combination chemotherapy. However, the clinical application of CDDP 
is greatly limited because of the associated side effects including hepatotoxicity, resistance, and 
nephrotoxicity. In their article, Lin et al acknowledge the potential of Andrographis paniculata 
as the anticancer agent of choice for use in treatment of colon carcinoma and prevention of side 
effects. The authors begin with a background review of the findings in recent studies assessing 
the anticancer effects of the herb widely used in the traditional treatment of a variety of medical 
conditions in countries in Southeastern Asia (Lin et al., 2013). The findings revisited by these 
researchers in their publication indicated that extracts from the plant induce arrest of the cell 
cycle and inhibit growth, cause death of various cancerous cells by apoptosis, increases the 
cytotoxic potency of cancer drugs such as TRAIL and fluorouracil against cancerous cells, and 
suppresses the invasion as well as migration of cancerous cells and may thus be used as an anti-
metastasis treatment (Lin et al., 2013). Moreover, a study recently demonstrated that 
andrographolide increases chemosensitivity of CRC cells to doxorubicin by inhibiting the  
STAT3 pathway (Zhou et al., 2010).  
 
       Taken together, the findings from these studies indicate that andrographolide has several 
targets and is strongly effective in increasing the cytotoxicity of drugs against cancer cells. The 
authors conducted experimental studies to assess the effect of andrographolide on the 
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effectiveness of CDDP using the MTT assay and described the specific signaling pathway 
involved in the apoptotic effects of a combination of CDDP and extracts from Andrographis 
paniculata in colorectal carcinoma cells. The results presented show a reduced viability of cells 
exposed to andrographolide together with low concentrations of CDDP in comparison with cells 
treated with either of the compound alone. The findings confirmed activation of apoptosis by 
Lovo cells exposed to CDDP and andrographolide. These cells show typical morphological 
changes corresponding to apoptosis such as shrinking of cells and blebbing of membranes, a rise 
in hypodiploid cells, and movement of phosphatidylinositol towards the outer cell membrane 
layer in the early stages of apoptosis, as well as caspase-3, caspase-8 and caspase-9 cleavage 
(Lin et al., 2013). From these observations, the authors concluded that the increase in the 
cytotoxicity of CDDP, caused by andrographolide, contributes to apoptosis induction in Lovo 
cells (Lin et al., 2013).  
1.7.4. Glioma Cells:  
        One of the most commonly occurring tumors affecting the central nervous system are 
gliomas, which may involve astrocytes, ependymal cells, oligodendrocytes, and other glial cells. 
These tumors are extensively infiltrative and frequently affect essential areas of the brain, and 
therefore surgical removal is not possible. Management of glioma patients relies heavily on 
adjuvant treatments including chemotherapy and radiotherapy. Other agents that target specific 
molecules and factors such as anti-vascular endothelial growth factor and epidermal growth 
factor receptor are also applied in the control of gliomas. However, patient management in these 
disease states is associated with an eventual treatment failure. Glioblastoma, a kind of glioma, is 
associated with very poor prognosis, and is the most highly malignant and common form of 
glioma. It has a 7.5 % two-year survival rate that drops to a five percent five-year survival rate, 
with most patients affected by glioblastoma dying within two years. The development of better 
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agents for the chemotherapeutic management of malignant gliomas are mandatory (Yang et al., 
2014).  
        In their report, Yang and co-authors studied the antitumor activities of andrographolide on  
C6 glioma cells, a glioblastoma experimental model, and the mechanisms underlying this activity 
(Yang, et al., 2014). The methodology of this study involved cell culture of C6 glioma cells, cell 
survival assays, apoptosis detection assays, transfection of small interfering RNA for p53, 
western blotting, and statistical analysis. The researchers found that andrographolide induced 
apoptotic death among C6 glioma cells, triggered caspase and PARP cleavage and activation and 
increased expression of p53. Treatment with andrographolide resulted in the inhibition of growth 
of the tumors and their regression, which is mediated by the apoptotic cell death induced by 
andrographolide. This compound’s cytotoxicity is selective to cells that are cancerous, and 
andrographolide has no effect on normal astrocytes, and as such its potential for clinical 
utilization as an antitumor agent is great (Yang et al., 2014).  
1.7.5. Intrahepatic Cholangiocarcinoma:  
        In their publication, Suriyo et al (2014) describe the inhibitory effects of different 
diterpenoids isolated from Andrographis paniculata on the growth of cancerous cells in 
intrahepatic cholangiocarcinoma. The main medical issue presented by the authors is 
cholangiocarcinoma, which includes intrahepatic, perihelia, as well as distal extrahepatic tumors 
affecting the epithelium of the bile ducts. This form of primary liver cancer is relatively rare, but 
its incidence rates in southeastern Asia, particularly in Thailand, are significantly high.  
Epidemiologic studies conducted recently have indicated an increase in the cholangiocarcinoma 
incidence rates and mortality rates around the globe. Cholangiocarcinoma is a highly aggressive 
malignancy that is typically characterized by poor prognosis as well as a persistent 
unresponsiveness to many radiotherapeutic and chemotherapeutic techniques. The treatment of 
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this condition is quite challenging. Therefore, there is an urgent need for an alternative effective 
therapy for cholangiocarcinoma (Suriyo et al., 2014).  
       The potential for use of Andrographis paniculata in the management of these cancer has 
renewed interest among researchers in search of medicinal herbs for use as anticancer agents. 
Together with its primary constituent diterpenoids, particularly AP1, Andrographis paniculata 
has been found to possess anticancer activity in models of different types of cancers. Suriyo, et al 
report the inhibitory effects of this herb and its main diterpenoids components at different stages 
in the growth of cancerous hepatic and bile duct cells (Suriyo et al., 2014).  
        The researchers prepared extracts of the herb at varying stages of plant growth and 
determined their diterpenoid content by use of HPLC. Analysis of MLWE (Mature Leaf Water 
Extract) and FTLEE (First True Leaf Ethanol Extract) from Andrographis paniculata revealed a 
higher content of AP1 in the Mature Leaf Water Extract than in the First True Leaf Ethanol  
Extract, while both AP3 and AP6 were present at relatively higher concentrations in the First 
True Leaf Ethanol Extract. By using an MTT assay, the cytotoxic activity of the two extracts on 
hepatic cell carcinomas and on intrahepatic cholangiocarcinoma were evaluated. The results 
showed a fourfold higher cytotoxicity of FTLEE on all cell lines in comparison to MLWE. A 
consequent analysis of the cytotoxic effects of the different diterpenoids on the cancerous 
hepatocytes and cholangiocytes demonstrated that AP1 had a significantly higher cytotoxic 
effect than the rest of the diterpenoid components of Andrographis paniculata. Due to these 
observations, Suriyo, et al speculated that the cytotoxic effect that Andrographis paniculata has 
on cancerous hepatocytes and cholangiocytes is a feature of AP1. An interesting finding made by 
these researchers is the difference in cytotoxic potency of the extracts obtained at different stages 
of growth of the plant (Suriyo et al., 2014). FTLEE, which was found to have a high AP6 content 
but low AP1 content in comparison to MLWE, inhibited growth more potently among the 
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cancerous hepatic and bile duct cells than its counterpart. While the presence of AP1 in MLWE 
explained its cytotoxic activity against cancer cells, this does not account for the difference that 
was observed for the cytotoxicity of the extracts. The authors hypothesized there were 
interactions occurring between the main active diterpenoids in the extracts, particularly AP1 and 
AP6, which have a role in the compounds’ growth inhibitory effect. The effect of other 
diterpenoids apart from the four on which this study focused could account for the difference in 
cytotoxic potency between FTLEE and MLWE. This hypothesis is not conclusive, and calls for 
further studies in this direction (Suriyo et al., 2014).  
       This study showed that the cytotoxic effect of FTLEE relied on cell cycle arrest and 
increased apoptosis in the cancerous cells. FTLEE induced arrest of the cell cycle at GO/G1 as 
well as in G2/M phases, and was followed by a decrease in the expression of cyclin D1.  
Experiments that were designed to assess the cytotoxic activity of AP1 in HuCCA-1 and 
RMCCA cells, revealed a significantly higher cytotoxic potency of this compound. This 
difference was hypothetically attributed to the varying etiology of the cancerous cells used, 
particularly their inflammatory background. The role of cyclooxygenase 2 in the inhibition of 
apoptosis mediated by Fas and the difference in the cyclooxygenase content between f HuCCA-1 
and RMCCA cells were also implicated in the observed differences in the cytotoxic potency of 
AP1 against these cancerous cell types (Suriyo et al., 2014). These studies demonstrate the 
necessity for supplementary studies to complement this publication and the dependence on the 
findings from other studies.   
1.7.6. Inflammation and cancer:  
        Studies have shown an association between inflammation and the development and 
progression of cancer (Rakoff -Nahoum, 2006). Inflammation is the host response to infection by 
microbes and mediates the repair and regeneration resulting from tissue damage.  The 
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inflammatory response involves the release of several growth and activating factors by the 
immune system that can result in cell activation. Inflammation can also promote tissue damage 
in addition to that caused by infection. Epidemiological evidence suggests a correlation between 
the inflammatory responses and predisposition to cancer development. Prolonged inflammation 
causes cell dysplasia. Moreover, an estimated 15% of cancer incidence in the global population 
is linked to infection by microbes or viruses. Chronic infection with hepatitis B virus (HBV), 
hepatitis C virus (HCV), and human papilloma virus (HPV) can cause hepatocellular carcinoma 
and cervical cancers. Opportunist infection by human herpes virus-8 (HHV 8) may result in the 
development of Kaposi’s sarcoma. Inappropriate responses by the immune system in some 
individuals result in the development of gastric cancer following colonization by Helicobacter 
pylori or colon-cancer development secondary to prolonged inflammatory bowel disease that are 
caused by microflora in the intestines (Rakoff-Nahoum, 2006).   
          In other cases, chronic irritation together with the inflammation that follows, predispose to 
cancer, as is the case with chronic exposure to asbestos, silica, and cigarette smoke. Signs of 
inflammation like leukocyte infiltration are a key feature of almost all types of tumors. The 
utilization of non-steroidal anti-inflammatory drugs in preventing the spontaneous formation of 
tumors in individuals having familial adenomatous polyposis presents another piece of evidence 
on the role of inflammation in cancer (Rakoff-Nahoum, 2006).   
          Inflammation and cancer development are linked by epidemiological evidence, 
histopathological changes, inflammatory profiles, as well as the effectiveness of anti-
inflammatory agents in cancer prophylaxis (Rakoff-Nahoum, 2006). Agents that are effective in 
the control of inflammatory responses are of considerable importance in the overall management 
of various cancers, and andrographolide, the most active component isolated from Andrographis 
paniculata, is one of these agents (Chen et al., 2014). Analysis shows that andrographolide has 
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inhibitory effects on vascular smooth muscle cells after exposure to a stimulus that causes 
inflammation (Chen et al., 2014). The main issue presented here is vascular inflammation, which 
at some critical level causes cardiovascular illnesses such as atherosclerosis, hypertension, and 
vascular dysfunction. After stimulating smooth muscle cells with tumor necrosis factor-α, 
andrographolide was administered, resulting in the suppression of inducible NO synthase 
expression in a manner that was concentration-dependent and involved induction of JNK-Akt 
and p65 phosphorylation (Chen et al., 2014).   
         These findings, were complemented by observations made following administration of 
LY294002 (an inhibitor of Akt activation), suggested that andrographolide can be effectively 
used in the therapy of inflammatory diseases affecting blood vessels by inhibiting NF-kB activity 
through the JNK-Akt and p65 signaling cascade (Chen et al., 2014). A similar study was 
conducted by Shen and co-authors in 2013 to determine the molecular mechanisms underlying 
andrographolide’s anti-inflammatory activity. The researchers used kinase assays, measurements 
of transcription factor levels in the nucleus, and luciferase reporter-promoter gene expression 
assays to determine the molecular targets of andrographolide. Andrographolide was found to 
suppress the release of NO, prostaglandin E2, and decreased tumor necrosis factor-α, interferon 
β, cyclooxygenase, and inducible NO synthase mRNA in peritoneal macrophages as well as in 
RAW264.7 cells activated by lipopolysaccharide, in a concentration-dependent manner (Shen et 
al., 2013). Andrographolide was also found to ameliorate symptoms of hepatitis induced by 
lipopolysaccharide and gastritis induced by HCl in mice. The study revealed that 
andrographolide’s anti-inflammatory effects were mediated by the IKKε/ IRF- 3 pathway. The 
authors concluded that there are novel pathways used by andrographolide in suppression of 
inflammatory responses (Shen et al., 2013). Therefore, as indicated by findings from these 
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studies, andrographolide is a potential anti-inflammatory agent having two pharmacological 
targets (Shen et al., 2013).  
  
1.8. Apoptosis  
        Apoptosis is derived from “dropping off” in Greek and refers to the falling of tree leaves in 
autumn (Wong, 2011). Moreover, the term, apoptosis, is used to explain the condition whereby a 
cell vigorously pursues a course toward death on receiving certain stimuli (Kerr, 1991; Wong, 
2011). Clearly, the idea that apoptosis is a gene-directed program to cause the death of a cell has 
had significant implications for the understanding of tissue homeostasis and in developmental 
biology (Lowe & Lin, 2000). The ability to induce apoptosis implies that the number of cells can 
be controlled by specific processes in addition to those that regulate differentiation and 
proliferation. Further, the genetic basis for apoptosis implies that the death of a cell, similar to 
any other developmental or metabolic program, can be upset by mutation (Lowe & Lin, 2000). 
Apoptosis pathway defects are now thought to be key contributors to numerous human illnesses, 
ranging from malignancy to neurodegenerative disorders (Lowe & Lin, 2000; Thompson,1995).  
A tumor is the result of aberrant growth of cells and can result from increases in cell proliferation 
or by disruption of normal processes of cell death and apoptosis.  
  
1.8.1. Morphological changes:  
         Apoptosis is characterized by a very specific set of morphological characteristics that 
includes changes in nuclear shape, condensation of chromatin, alongside the fragmentation of the 
nucleus that are accompanied by cellular volume reduction, cell rounding and retraction of 
pseudopods (Kroemer et al., 2005; Wong, 2011). The condensation of the chromatin begins at 
the nuclear membrane periphery, forming a ring or crescent-like structure. It further condenses 
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until it breaks up inside the cell even though the plasma membrane remains intact, a 
characteristic known as karyorrhexis (Manjo & Joris., 1995). Notably, although the plasma 
membrane remains intact during most of the process, there are numerous morphological features 
in the late phases of apoptosis which include loss of membrane integrity, organelles, cytoplasmic 
ultrastructure modification, and membrane blebbing (Kroemer et al., 2005). Typically, 
phagocytic cells engulf apoptotic cell fragments prior to the release from the apoptotic bodies  
(Wong, 2011).  
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                                 Figure 1.5. Morphological changes in apoptotic cells.  
                                          https://en.wikipedia.org/wiki/Apoptosis  
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1.8.2. Biochemical changes:  
         Three key biochemical changes can be observed during apoptosis which includes; the 
activation of caspases, protein and DNA breakdown, and membrane changes to promote 
recognition by phagocytic cells (Wong, 2011; Kumar et al., 2014). In the early stages of 
apoptosis, phosphatidylserine (PS) becomes expressed on the exterior side of the plasma 
membrane because it has been flipped from the cytoplasmic side (Gerl & Vaux, 2005; Wong, 
2011). The presence of PS on the surface of the cell (and apoptotic bodies) permits macrophages 
to recognize and phagocytose the apoptotic cells before they can release DNA or proteins which 
would activate the immune system and promote the release of pro-inflammatory cytokines 
(Hengartner, 2001). PS expression on the cell surface is followed by DNA breakdown into large 
kilobase pieces (Vaux-Silke, 2003) and later, by internucleosomal cleavage of the DNA into 
oligonucleosomes of approximately 150 bp (Wong, 2011). Additionally, another feature of 
apoptosis is the activation of a group of enzymes that belong to the family of cysteine protease 
called caspases. Activated caspases cleave numerous essential cellular proteins in addition to 
breaking up the nuclear scaffold and cellular cytoskeleton. Furthermore, caspases can activate  
DNAase that further degrade nuclear DNA (Lavrik et al., 2005; Wong, 2011).  
1.8.3. Apoptotic Mechanisms:  
         The apoptotic process can be induced either by external or internal cell signals. In the case 
of the external death (extrinsic) pathway, apoptosis is initiated when extracellular proteins called 
death ligands attach to the death receptor on the target cell. Even though there are numerous 
known death receptors, the most commonly recognized ones are the type 1 TNF receptor 
(TNFR1) and a related protein known as Fas (CD95). Additionally, their ligands are TNF-like 
molecules and Fas ligands (FaSL) (Hengartner, 2003; Wong, 2011). Death receptors bind the 
death ligands and result in the formation of a death-inducing signaling complex in the target cell 
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cytoplasm which initiates the apoptotic process by activating caspase 8. When caspase 8 is 
activated, it is able to activate other downstream caspases to ultimately destroy the cells (Wong,  
2011).  
          On the other hand, the interior activated (or intrinsic) pathway begins inside the cell. 
Accordingly, internal stimuli including irreparable genetic destruction, escalated concentrations 
of cytosolic calcium, hypoxia, and severe oxidative stress are some triggers that initiate the 
pathway (Wong, 2011; Karp et al., 2014). Although there are many different activators, they all 
result in an increase in mitochondrial permeability and the release of pro-apoptotic molecules 
including cytochrome-c into the cytoplasm (Danial-Korsmeyer, 2004). Cytoplasmic cytochrome 
c, in turn, attaches to cytoplasmic proteins including Apaf-1 and caspase 9, a process that results 
in the formation of the apoptosome. Finally, the formation of the apoptosome activates the 
caspases responsible for initiating the apoptosis process (Kroemer et al., 2007; Wong, 2011).  
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                      Figure 1.6. The apoptosis pathways [extrinsic, intrinsic] (Wong., 2011).  
                        http://jeccr.biomedcentral.com/articles/10.1186/1756-9966-30-87   
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1.8.4. Caspases:  
        Before its activation, a caspase exists within a cell in an inactive form known as procaspase.  
The procaspase contains an N-terminal leader peptide that acts to inhibit its enzymatic activity.   
The activation of the procaspase involves enzymatic cleavage of this peptide to allow activity: 
active caspases are always smaller than procaspases. There are different types of caspases, and 
the formation of the apoptosome activates some of them, including caspase-8, caspase-9, 10 and 
2. These initiator caspases, in turn, cleave and activate other caspases, including caspase-3,  
caspase-6 and caspase-7. Once activated, the effector caspases degrade the cell's components, 
resulting in the destruction of its DNA, chromosomes, and membrane. The cell dies and is 
removed by phagocytosis (Fink& Cookson, 2005; Wong, 2011).   
  
Summary:  
         Andrographolide, which is the most abundant and active component isolated from extracts 
of Andrographis paniculata, has a wide variety of pharmacological activities and has been 
utilized in the traditional management of several medical conditions in countries in Southeastern 
Asia. This component of Andrographis paniculata has been shown to have anticancer effects 
against several cancer types, including intrahepatic cholangiocarcinoma, gliomas, and human 
colorectal carcinoma, and the mechanism mainly involves enhancement of apoptosis and 
arresting of the cell cycle. By use of mechanisms that inhibit NO production and expression of 
factors such as TNF and cyclooxygenase, Andrographolide also has anti-inflammatory activity.  
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1.9. Research objectives:   
       This research centers around the effect of Andrographis paniculata on the growth of 
malignant cancer cells and examines the mechanisms underlying these effects. The research 
questions are fashioned based on the actions of 70% ethanol extracts and aqueous extracts of 
Andrographis paniculata on malignant cancer cells, especially B16-BL6 cells. A key hypothesis 
of this study is that Andrographis paniculata extracts suppress the growth or induce the death of 
the malignant cancer cells.  
• The purposes of this research are to:  
1- Study the effect of 70% ethanol extract and aqueous extract of Andrographis paniculata 
on the growth of malignant cancer cells including B16-BL6, ASPC-1, 4T1, MCF-7, and 
MDA-MB-231 cell lines.  
2- Determine the effect of Andrographis paniculata extracts on B16-BL6 murine melanoma 
cell morphology.  
3- Examine caspase 3 activation and inhibition of ERK phosphorylation to investigate 
whether Andrographis paniculata extracts block survival signals and induce apoptosis as 
a mechanism of action in B16-BL6 murine melanoma cells.  
4- Determine the effect of 70% ethanol extract and aqueous extract of Andrographis 
paniculata on the B16-BL6 cell cycle profile.  
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Chapter 2: Materials and Methods  
2.1. Cancer cell lines:  
The malignant cancer cell lines presented in this chapter are the following:  
1. B16-BL6 cell line: These cells originated from malignant mouse epidermal melanocytes 
and have the property of invading secondary organs like liver, lungs, and brain  
(Kushiro& Nunez., 2012).  
2. ASPC-1 cell line: Isolated from the ascites cells from a 62-year-old Caucasian women 
with pancreatic cancer. The cells were shown to be pancreatic cancer cells that were able 
to express carcinoembryonic antigen (CEA) (Public Health England., 2016).  
3. MCF-7 cell line: These cells were derived in 1970 from the breast tissue, of a 69-yearold 
Caucasian woman with triple positive cancer who presented the malignant 
adenocarcinoma in the pleural effusion (Altogen Biosystems., 2016).  
4. 4T1 cell line: These are triple negative murine breast cancer cells that are transplantable, 
extremely tumorigenic and can metastasize from mammary gland tumors to secondary 
organs like lymph nodes, brain, bone, liver and lungs (Pulaski-Rosenberg., 2001).  
5. MDA-MB-231 cell line: These cells were derived from the pleural effusion of a 51-
yearold woman with triple negative breast cancer malignant breast cancer (Public Health 
England., 2016).  
  
2.2. Tissue culture:  
       B16-BL6, MCF-7, MDA-MB-231, ASPC-1 and 4T1 cell lines were purchased from the 
American type culture collection (Manassas, VA 20110, United States) an American company 
that specializes in the sale of cells, microorganisms, culture reagents, and other related products.  
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B16-BL6, MCF-7 and MDA-MB-231 cell lines were maintained in Dulbecco's modified Eagle's 
medium (DMEM, Hyclone, Logan, UT), supplemented with 10% fetal bovine serum (Hyclone),  
100 μg/ml streptomycin, and 100 U/ml penicillin (Invitrogen, Burlington, ON). ASPC-1 and 4T1 
were maintained in RPMI medium (Hyclone, Logan, UT), supplemented with 10% fetal bovine 
serum (Hyclone) 100 μg/ml streptomycin, and 100 U/ml penicillin. Thereafter, all cell lines were 
incubated in a humid atmosphere at 37°C and 5% CO2. The cells were subcultured by removing 
the media from the cell culture plate, washing the cells with PBS to remove all media traces, 
adding 7 ml of trypsin to the cell culture plate and placed in the incubator for five minutes, 
collecting the trypsin and a wash of 7 ml of culture media into a centrifuge tube, and then 
pelleting the cells by centrifugation at 400xg for 10 min. New media was added to the cells and 
an aliquot added to a new culture plate containing media and then incubated in a humid incubator 
at 37˚C, 5% CO2. During the incubation period, the cells were subcultured every three-to-five 
days, depending on the growth rate of the cells.   
2.3. Plant Materials:   
      Different sources of Andrographis paniculata were used in these experiments:  
1- Andrographis paniculata containing 33% andrographolide and derived from the whole plant.  
This plant preparation was purchased from Durham Natural Foods (1191 Montrose Avenue,  
Sudbury, Canada, Ontario: 80040811).  
2- Andrographis paniculata extract containing 10% andrographolide and derived from the aerial 
parts of plant. This plant preparation was purchased from Nutrition House (Dundas St W,  
Toronto, Canada, ON: 80029281).  
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2.4. Plant extract preparation:  
      Two categories of Andrographis paniculata extraction prepared for these experiments:  
1- Preparation of aqueous (PBS) extract of Andrographis paniculata:  
600 mg of Andrographis paniculata powder mixed with 6 ml of PBS.  
2- Preparation of 70% Ethanol extract of Andrographis paniculata:  
600 mg of Andrographis paniculata mixed with 6 ml of 70% EtOH.  
Both mixtures were boiled for one hour, made up to the appropriate level with solvent, and then 
filtered through a 0.22 uM syringe filter.  The extracts were aliquoted and stored at -80˚C. To 
evaluate the stability of the plant, some of the extracts stored at 4˚C and tested at multiple time 
points.   
  
2.5. MTT cell viability assay (Methyl Tetrazolium Blue):  
        The overall aim of the experiment was to measure the effects of the aqueous or ethanol 
extracts of Andrographis paniculata on cell proliferation. To achieve this aim, the proliferation 
of the B16-BL6, ASPC-1, MDA-MB-231, MCF-7 and 4T1 cell lines was used to examine the 
effect of the extracts of Andrographis paniculata (33% andrographolide) stored at -80°C.  
Additionally, Andrographis paniculata extracts stored at 4°C for 3 months were tested on the  
B16-BL6 cell line to assess the stability of the plant extract. However, another source of 
Andrographis paniculata containing 10% andrographolide was also tested on B16-BL6 cell line 
and compared to the other source. Moreover, media controls (untreated cells) were used as a 
negative control. Some cells were tested with equivalent amounts of PBS in media or ethanol in 
media to control for the solvent used to extract the Andrographis paniculata.  
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Method:   
       Over 103 cells/well were plated in each well of the 5 different 96 well plates and allowed to 
grow in the media at 37°C and 5% CO2 for 24 hours. Thereafter, some cells were treated with the 
PBS extract of Andrographis paniculata while other cells were treated with the 70% Ethanol 
extract of Andrographis paniculata at various concentrations (0.1, 0.25, 0.50, 0.75, and 1%).  
During a five-day incubation period, one of the plates was subjected to the MTT assay each day. 
For the assay, 10 ul of MTT solution (0.125 mg of MTT powder mixed with 50 ml of PBS and 
stored at 4°C in the dark) added to each plate and incubated for 4 hours. The MTT solution was 
removed from the wells and 100 ul DMSO (dimethyl sulfoxide) added to each well to solubilize 
the formazan crystals. Subsequently, the absorbance corresponding to the MTT product, 
corresponding to cells treated with different concentrations of Andrographis paniculata extracts 
was analyzed by performing ANOVA using Graph Pad Prism Software.  
2.6. Cell Morphology:  
        The overall aim of this experiment was to assess the effect of Andrographis paniculata 
extracts (aqueous-ethanol) on the morphological changes in the cells (shape and appearance) 
under the microscope. To realize this objective, Andrographis paniculata extracts were used to 
treat B16-BL6 and MDA-MB-231 cell lines for two days.  
Method:   
       The B16-BL6 and MDA-MB-231 cell lines were cultured and allowed to grow in DMEM 
media at 37°C and 5% CO2 for 24 hours. Thereafter, some of the cells were treated with the PBS 
extract of Andrographis paniculata while other cells were treated with the ethanol extract of 
Andrographis paniculata at low and high concentrations for 48 hours. Media controls (untreated 
cells) were used as a negative control. After 48 hours, an Olympus DP80 microscope was used to 
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image the treated and untreated cells. Thereafter, the observations were recorded with the aid of 
Cell Sens Dimension computer software.  
  
2.7. Acridine Orange/Ethidium Bromide staining assay:  
        The acridine orange and ethidium bromide staining assay was used to visualize nuclear 
changes (morphological changes) and apoptotic body formation that are characteristic of 
apoptosis in B16-BL6 cells.  
• Acridine orange: is a vital stain that stains both live and dead cell’s nucleic acids green.  
• Ethidium bromide: is a vital stain that stains DNA red only in cells that have lost membrane 
integrity.  
Method:   
         B16-BL6 cells were plated on sterile glass cover slips in 60x15 mm tissue culture plates in  
DMEM culture media and allowed to grow in the incubator at 37°C and 5% CO2 for 24 hours. 
The cells were then divided into three groups. The first group of cells were treated with the 
ethanol extract of Andrographis paniculata while the second group of cells was treated with the 
aqueous extract at low and high concentrations for 48 hours. Media controls (untreated cells) 
were incubated for 48 h and used as a negative control. After the 48-hour treatment, the cells 
were stained by incubation in culture media containing 10 ug/ml of Acridine orange (Sigma 
Aldrich) and 10 ug/ml of Ethidium bromide (Sigma-Aldrich) for 15 minutes. The coverslips 
were washed with PBS and mounted in a drop of (80% glycerol in PBS) on the microscopic 
slides. Then, clear nail polish was added on the slides to seal the coverslips. The fluorescence 
was visualized using an LSM510 microscope.   
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2.8. Western Blot Analysis:  
         The overall aim of this experiment was to analyze changes in specific proteins from the cell 
lysate. To achieve this aim, Andrographis paniculata extracts were tested on B16-BL6 cells and 
cell lysates prepared and analyzed.  
Method:  
         B16-BL6 cells were cultured and maintained in DMEM media and allowed to grow at 37°C 
and 5% CO2 for 24 hours. The cell cultures were divided into four groups. The first group of the 
cells was treated with the ethanol extract of Andrographis paniculata at various concentrations 
and the cells in the second group were treated with the PBS extract of  
Andrographis paniculata at various concentrations for 24 hours and 48 hours. In addition, a UV 
exposed plate of cells was utilized as a positive control for induction of cell apoptosis and a 
media control (untreated cells) was used as a negative control. After treatment, the B16-BL6 
cells were harvested, collected by centrifugation, and homogenized in 300 ul of lysis buffer 
(RIPA buffer: 150 mM sodium chloride, 50 mM Tris-HCl, pH 7, 1% Triton x-100, 0.5% sodium 
dodecyl sulphate, 0.5% sodium deoxycholate) with ¼ tablet of protease inhibitors (Roche).  
Subsequently, a 10% of polyacrylamide gel containing sodium dodecyl sulphate (SDS) (10% 
AcryI Bis, 0.125 M Tris- HCl, pH 8.8, 2% SDS, 0.005% TEMED, 0.01% APS) was utilized to 
separate the proteins in the cell lysate. A sample of each cell lysate, was normalized for cell 
number, boiled in sample buffer (0.125 M Tris-HCl, pH6.8, 4% SDS, 20% glycerol, and 0.1 
mg/ml bromophenol blue), and loaded into the wells of the gel. The gels were electrophoresed in 
running buffer (Tris-Glycine/SDS) at 90 volts for approximately 1 ½ hours. Thereafter, the 
proteins were transferred from the gel to a nitrocellulose membrane using a Bio Rad semi-dry 
transfer machine for 45 minutes at 12v. The membrane was then stained with 0.1% red ponceau 
S in 1% acetic acid stain for 10 min and then rinsed with sterile water. A gel documentation 
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system was utilized to take a photo of the membrane to prove that the lanes of the gel were 
equally loaded. The membrane was blocked with 5% BSA in Tris-buffered saline containing 
Tween-20 (TBST, 50 mM Tris-HCl, pH7.5, 150 mM sodium chloride, 0.1% Tween-20) solution 
and incubated at room temperature for 1 hour. Next, the blots were incubated with one of the 
following primary antibodies (1:1000 dilution of caspase 3 monoclonal mouse antibody, 1:1000 
dilution of phosphorylated-ERK monoclonal mouse antibody or 1:1000 dilution of ERK1/2 
polyclonal goat antibody) overnight at 4°C on a rocker platform. The membrane washed with 
TBST three times for 10 min each. A suitable secondary antibody (1:10.000 dilution of goat anti-
mouse IgG-HRP or rabbit anti-goat IgG-HRP conjugate) in 5% BSA in TBST was incubated 
with the membrane at 4°C for 1 hour. The membrane was washed with TBST for three times for 
10 min each. A TBS solution was incubated with the membrane for 5 mins. The membrane was 
placed face down in the ECL reagent for 5 mins and face up for 2 mins and then inserted in a 
plastic sheet into the X-ray cassette with a sheet of X-ray film placed on top of the membrane, 
and then exposed.  The film was developed using an XOMAT film developing machine.  
  
2.9. Flow Cytometry:  
        The objective of this experiment was to determine the effect of Andrographis paniculata 
(PBS and ethanol extracts) on the cell cycle distribution of B16-BL6 cells by measuring the 
DNA content.   
       The propidium iodide (staining solution) is a fluorescent dye that intercalates into the DNA 
so that the level of fluorescence corresponds to the amount of DNA. It can also stain the 
apoptotic cells, which have decreased DNA content due to nuclear fragmentation (creating a sub  
G1 peak).  
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Method:   
       B16-BL6 cells were cultured in 60x15 mm tissue culture plates by incubating them at 37°C 
and 5% CO2 for 24 hours. Then, the cell cultures were divided into four groups.  One group of 
cells was treated with the PBS extract of Andrographis paniculata at low and high doses while 
the cells in the second group were treated with the ethanol extract of Andrographis paniculata at 
low and high concentrations. Further, untreated cells were used as a negative control whereas a 
UV exposed sample was used as a positive control for apoptosis. After treatment, the cells were 
washed with PBS and trypsin was used to harvest them. The cells were pelleted by centrifugation 
at 400xg for 5 minutes and washed with PBS. The B16-BL6 cells were then fixed by incubation 
in cold 70% ethanol and stored at -20°C until used. Subsequently, the cells were washed with 
PBS and then 0.5 ml of PBS and 0.5 ml of PI solution (distilled water, 1 ug/ml RNAase, 10 
ug/ml propidium iodide, 0.05% Triton 100, and 150 mM NaCl) were added to each centrifuge 
tube and incubated for 30 min in the dark. Finally, the samples were filtered through a 0.5 um 
filter sheet with the aid of a filter syringe and then transferred to the flow tube. The stained B16- 
BL6 cells were analyzed using a Beckman coulter LS600 flow cytometer.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45  
  
Chapter 3: Results  
3.1. Cancer cell viability (70% ethanol extract versus PBS extract):  
         The MTT assay was used to determine the effect of Andrographis paniculata extracts on 
the cancer cell’s viability. B16-BL6 murine melanoma cells were treated with two different 
extracts (ethanol & PBS) of Andrographis paniculata containing 33% andrographolide at low 
concentration, middle and high concentration. Treatment of cells with the ethanol extract of 
Andrographis paniculata revealed a significant inhibition of cell growth at high concentration 
and middle concentration while the low dose of the ethanol extract promoted an much smaller 
decrease in cell number (Figure 3.1.). However, treatment of the cells with the aqueous extract of 
Andrographis paniculata showed a significant decrease in the cell number only at the highest 
concentration while treatment with the PBS extract at the middle concentration showed a slight 
decrease in cell number while the cell number at the low dose of PBS extract was the same as the 
untreated cells (Figure 3.2.).  
         To evaluate the stability of the drug, B16-BL6 cells treated with Andrographis paniculata 
extracts (ethanol, aqueous) that had been stored at 4˚C for approximately 3 months. The findings 
suggested that the viability assay of cells treated with the ethanol extract and aqueous extract was 
similar to the drug extracts that were stored at -80˚C (Figure 3.3. and 3.4.). Consequently, the 
effects of Andrographis paniculata extracts were stable in the extracts when stored at 4˚C and 
still had the ability to inhibit cell growth.  
        In addition, B16-BL6 cells that were treated with different source of Andrographis 
paniculata containing 10% andrographolide extracts (aqueous, ethanol), presented results that 
were similar to extract made for Andrographis paniculata obtained from the second source  
(Figure 3.5.and 3.6.). However, this plant extract displayed a little difference, which suggested 
that the ethanol extracts have a similar ability to inhibit cell growth at all concentration levels 
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while the aqueous extract only inhibited cell growth at the highest concentration and middle 
concentrations.   
           ASPC-1 cells that were treated with the ethanol extract of Andrographis paniculata 
showed an inhibition of cell growth at low, middle, and high concentration in comparison to 
untreated cells that showed a typical increase in cell number (Figure 3.7.). In addition, an 
analysis of the effect of the aqueous extract of Andrographis paniculata on ASPC-1 cells at high 
concentration suggested that there was a decline in the cell number (Figure 3.8.). However, 
treatment with the aqueous extract at low and middle concentration demonstrated that there was 
a much weaker effect on cell growth. MCF-7 (human breast cancer-triple positive) cells that 
were treated with Andrographis paniculata extracts showed strong inhibition of growth when 
treated with high, medium and low concentrations of the ethanol extract (Figure 3.9.) but only 
strong inhibition when treated with high concentration of the aqueous extract (Figure 3.10.), 
similar to the observations with the ASPC-1 cells.  
        However, 4T1 (mouse breast cancer-triple negative) and MDA-MB-231 (human breast 
cancer-triple negative) cells treated with the ethanol extract of Andrographis paniculata showed 
a significant inhibition in cell growth at high and middle concentrations but a weaker effect at the 
low concentration (Figure 3.11. and 3.13.). In contrast, treatment of 4T1 and MDA-MB-231 cells 
with the aqueous extract of Andrographis paniculata did not significantly inhibit the cell growth, 
which implies that the cells continue proliferation (Figure 3.12. and 3.14.).  
        In summary, these findings demonstrated that the effect of ethanol extract of Andrographis 
paniculata on the cancer cells was greater than the effect of the aqueous extract. Further, the 
results suggested that there were significant variation in sensitivity between the cell lines.  
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Figure 3.1. The effect of ethanol extract of Andrographis paniculata containing 33% 
andrographolide on B16-BL6 cells growth.  
     B16-BL6 murine melanoma cells were treated with the ethanol extract of Andrographis 
paniculata (33% andrographolide) that was derived from the whole plant, at low (0.1%), middle 
(0.50%) and high (1%) concentrations for five days. The B16-BL6 cells viability was determined 
by MTT assays each day for five days. The data were analyzed using Graph Pad Prism for 3 
independent experiments.  
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Figure 3.2. The effect of aqueous extract of Andrographis paniculata containing 33% 
andrographolide on B16-BL6 cells growth.  
     B16-BL6 murine melanoma cells were treated with the PBS extract of Andrographis 
paniculata (33% andrographolide) that was derived from the whole plant, at low (0.1%), middle 
(0.50%) and high (1%) concentrations for five days. The B16-BL6 cells viability was determined 
by MTT assays each day for five days. The data were analyzed using Graph Pad Prism for 3 
independent experiments.  
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Figure 3.3. The stability of ethanol extract of Andrographis paniculata that stored at room 
temperature for 3 months.  
     B16-BL6 murine melanoma cells were treated with the ethanol extract of Andrographis 
paniculata (33% andrographolide) that had been incubated at 4˚C for approximately 3 months. 
The cells were incubated with low (0.1%), middle (0.50%) and high (1%) concentrations of the 
extract for five days. The B16-BL6 cells viability was determined by MTT assays each day for 
five days. The data were analyzed using Graph Pad Prism for 3 independent experiments.  
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Figure 3.4. The stability of aqueous extract of Andrographis paniculata that stored at room 
temperature for 3 months.  
     B16-BL6 murine melanoma cells were treated with the PBS extract of Andrographis 
paniculata (33% andrographolide) that had been incubated at 4˚C for approximately 3 months. 
The cells were treated with low (0.1%), middle (0.50%) and high (1%) concentrations of the 
extract for five days. The B16-BL6 cells viability was determined by MTT assays each day for 
five days. The data were analyzed using Graph Pad Prism for 3 independent experiments.  
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Figure 3.5. The effect of ethanol extract of Andrographis paniculata containing 10% 
andrographolide on B16-BL6 cells growth.  
     B16-BL6 murine melanoma cells were treated with the ethanol extract of Andrographis 
paniculata (10% andrographolide) that was derived from the aerial part of the plant at low 
(0.1%), middle (0.50%) and high (1%) concentrations for five days. The B16-BL6 cells viability 
was determined by MTT assays each day for five days. The data were analyzed using Graph Pad 
Prism for 3 independent experiments.  
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Figure 3.6. The effect of aqueous extract of Andrographis paniculata containing 10% 
andrographolide on B16-BL6 cells growth.  
     B16-BL6 murine melanoma cells were treated with the PBS extract of Andrographis 
paniculata (10% andrographolide) that was derived from the aerial part of the plant at low 
(0.1%), middle (0.50%) and high (1%) concentrations for five days. The B16-BL6 cells viability 
was determined by MTT assays each day for five days. The data were analyzed using Graph Pad 
Prism for 3 independent experiments.  
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Figure 3.7. The effect of ethanol extract of Andrographis paniculata on ASPC-1 cells 
growth.  
     ASPC-1 (pancreatic cancer cells) were treated with the ethanol extract of Andrographis 
paniculata (33% andrographolide) that was derived from the whole plant at low (0.1%), middle 
(0.50%) and high (1%) concentrations for five days. The ASPC-1 cells viability was determined 
by MTT assays each day for five days. The data were analyzed using Graph Pad Prism for 3 
independent experiments.  
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Figure 3.8. The effect of aqueous extract of Andrographis paniculata on ASPC-1 cells 
growth.  
     ASPC-1 (pancreatic cancer cells) were treated with the PBS extract of Andrographis 
paniculata (33% andrographolide) that was derived from the whole plant at low (0.1%), middle 
(0.50%) and high (1%) concentrations for five days. The ASPC-1 cells viability was determined 
by MTT assays each day for five days. The data were analyzed using Graph Pad Prism for 3 
independent experiments.  
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Figure 3.9. The effect of ethanol extract of Andrographis paniculata on MCF-7 cells growth.  
     MCF-7 (human breast cancer cells- triple positive) were treated with the ethanol extract of  
Andrographis paniculata (33% andrographolide) that was derived from the whole plant at low 
(0.1%), middle (0.50%) and high (1%) concentrations for five days. The MCF-7 cells viability 
was determined by MTT assays each day for five days. The data were analyzed using Graph Pad 
Prism for 3 independent experiments.  
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Figure 3.10. The effect of aqueous extract of Andrographis paniculata on MCF-7 cells 
growth.  
     MCF-7 (human breast cancer cells- triple positive) were treated with the PBS extract of  
Andrographis paniculata (33% andrographolide) that was derived from the whole plant at low 
(0.1%), middle (0.50%) and high (1%) concentrations for five days. The MCF-7 cells viability 
was determined by MTT assays each day for five days. The data were analyzed using Graph Pad 
Prism for 3 independent experiments.  
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Figure 3.11. The effect of ethanol extract of Andrographis paniculata on 4T1 cells growth.  
     4T1 (mouse breast cancer cells- triple negative) were treated with the ethanol extract of  
Andrographis paniculata (33% andrographolide) that was derived from the whole plant at low 
(0.1%), middle (0.50%) and high (1%) concentrations for five days. The 4T1 cells viability was 
determined by MTT assays each day for five days. The data were analyzed using Graph Pad 
Prism for 3 independent experiments.  
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Figure 3.12. The effect of aqueous extract of Andrographis paniculata on 4T1 cells growth.  
     4T1 (mouse breast cancer cells- triple negative) were treated with the PBS extract of  
Andrographis paniculata (33% andrographolide) that was derived from the whole plant at low 
(0.1%), middle (0.50%) and high (1%) concentrations for five days. The 4T1 cells viability was 
determined by MTT assays each day for five days. The data were analyzed using Graph Pad 
Prism for 3 independent experiments.  
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Figure 3.13. The effect of ethanol extract of Andrographis paniculata on MDA-MB-231 cells 
growth.  
     MDA-MB-231 (human breast cancer cells- triple negative) were treated with the ethanol 
extract of Andrographis paniculata (33% andrographolide) that was derived from the whole 
plant at low (0.1%), middle (0.50%) and high (1%) concentrations for five days. The MDA-
MB231 cells viability was determined by MTT assays each day for five days. The data were 
analyzed using Graph Pad Prism for 3 independent experiments.  
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Figure 3.14. The effect of aqueous extract of Andrographis paniculata on MDA-MB-231 
cells growth.  
     MDA-MB-231 (human breast cancer cells- triple negative) were treated with the PBS extract 
of Andrographis paniculata (33% andrographolide) that was derived from the whole plant at low 
(0.1%), middle (0.50%) and high (1%) concentrations for five days. The MDA-MB-231 cells 
viability was determined by MTT assays each day for five days. The data were analyzed using 
Graph Pad Prism for 3 independent experiments.  
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Figure 3.15. Comparison of the effect of Andrographis paniculata extracts on MCF-7 (triple 
positive breast cancer) and (MDA-MB-231) triple negative breast cancer.  
     MDA-MB-231 (human breast cancer cells- triple negative) and MCF-7 (human breast cancer 
cells- triple positive) were treated with Andrographis paniculata extracts (ethanol and PBS) at 
middle (0.50%) and high (1%) concentrations for five days. The cells viability was determined 
by MTT assays each day for five days. The data were analyzed using Graph Pad Prism for 3 
independent experiments.  
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3.2. Morphological changes of B16-BL6 & MDA-MB-231 cells upon exposure to  
Andrographis paniculata extracts:  
        B16-BL6 and MDA-MB-231 cells were treated with various doses of Andrographis 
paniculata extracts (both ethanol & aqueous) for 48 hours to assess the effect of treatment on 
B16-BL6 and MDA-MB-231 cell morphology using an Olympus DP80 microscope. The results 
demonstrated that the B16-BL6 cells treated with a high dose of the ethanol extract exhibited a 
significant decrease in cell number, the appearance of tangled apoptotic cells, and a decline in 
the cellular content of the cells (Figure 3.16.). This outcome was similar to that seen following 
the treatment with a high dose of the aqueous extract of Andrographis paniculata (Figure 3.16.). 
However, the decline in cells in the sample treated with the aqueous extract was not as great as 
the cell number decline that was observed with ethanol extracts. B16-BL6 that were treated with 
the ethanol extract and aqueous extract of Andrographis paniculata at low doses showed similar 
results. The results demonstrated that the B16-BL6 cells treated with the ethanol extracts and 
aqueous extracts of Andrographis paniculata, at low doses, exhibited cell shape changes, which 
manifested in the form of an elongated shape. Based on the appearance of the elongated cells, we 
concluded that they were under physiological stress.  
          In contrast, the MDA-MB-231 cells treated with high and low doses of the aqueous extract 
of Andrographis paniculata did not exhibit any significant changes in cell shape (Figure 3.17). 
The results demonstrated that, at low and high concentrations, the cells retained their shape and 
number throughout the experiment. In fact, their appearance was similar to untreated cells. 
However, exposure of MDA-MB-231 cells to high doses of the ethanol extract of Andrographis 
paniculata showed a significant decline in cell number in comparison to treatment with the low 
dose of the ethanol extract.  
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Figure 3.16. The effect of Andrographis paniculata extracts on the morphology of B16-BL6 
murine melanoma cells.  
      B16-BL6 cells were treated with Andrographis paniculata extracts (ethanol and PBS 
extracts) at low and high doses for 48 h. Untreated cells were used as a negative control. The 
experiment was run 3 time and the results were observed under Olympus DP80 Microscope. The 
bar in the bottom corner marks a field size of 20 µm.  
  
  
  
  
  
  
  
  
  
  
  
  
79  
  
 
  
  
 
  
  
  
  
A  
              Negative Control            Low Dose of ethanol  extract         High Dose of ethanol  extract  
      
               Negative Control             Low Dose of ethanol  extract       High Dose of ethanol  extract  
         
80  
  
 
  
  
 
  
  
  
  
  
  
B  
           Negative Control          Low Dose of PBS extract            High Dose of PBS extract  
      
             Negative Control          Low Dose of PBS extract             High Dose of PBS extract  
      
81  
  
 
Figure 3.17. The effect of Andrographis paniculata extracts on the morphology of MDAMB-
231(human breast cancer-negative triple).  
      MDA-MB-231 cells were treated with Andrographis paniculata extracts (ethanol and PBS 
extracts) at low and high doses for 48 h. Untreated cells were used as a negative control. The 
experiment was run 3 times and the results were observed under Olympus DP80 Microscope.  
The bar in the bottom corner marks a field size of 20 µm.  
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3.3. Treatment of B16-BL6 cells with Andrographis paniculata extracts for > 48h resulted in 
apoptotic morphology:       
      The acridine orange and ethidium bromide staining assay was used to test the effect of 
Andrographis paniculata extracts on B16-BL6 cell morphology. Untreated B16-BL6 cells 
showed a relatively even green stain in the nucleus, corresponding to acridine orange binding. 
The absence of any red staining corresponding to ethidium bromide staining was evidence that 
the plasma membrane was intact (Figure 3.18). The B16-BL6 cells that were treated with a high 
dose of the ethanol extract of Andrographis paniculata presented significant changes in cell 
morphology. The observed changes included the complete destruction of cell structure, and the 
appearance of orange staining in cells because of the loss of membrane integrity. However, we 
did not observe any morphological changes in the B16-BL6 at low dose of ethanol extract. (The 
cells appeared uniformly green; a clear sign for an intact nucleus in the cells). The exposure of 
B16-BL6 cells to a high concentration of the aqueous extract of Andrographis paniculata 
suggested that treatment led to the appearance of green cells with bright green dots in the nuclei 
because of chromatin condensation and nuclear fragmentation (Figure 3.19.). This result was 
evidence an early apoptosis compare to untreated cells, which showed normal nuclear staining.  
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Figure 3.18. The treatment of B16-BL6 murine melanoma cells with the ethanol extract of 
Andrographis paniculata > 48 h resulted in apoptotic morphology.  
     B16-BL6 cells were treated with the ethanol extract of Andrographis paniculata at low and 
high concentrations for 48 h. Untreated cells were used as a negative control. Acridine orange 
and ethidium bromide were used to stain B16-BL6 cells to look at nuclear morphology and 
plasma membrane integrity under the fluorescence microscope. This represents one of more than 
three independent experiments.  
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Figure 3.19. The treatment of B16-BL6 murine melanoma cells with the aqueous extract of 
Andrographis paniculata > 48 h resulted in apoptotic morphology.  
     B16-BL6 cells were treated with the PBS extract of Andrographis paniculata at low and high 
concentrations for 48 h. Untreated cells were used as a negative control. Acridine orange and 
ethidium bromide staining were used to detect B16-BL6 cell death under fluorescence 
microscope. The experiment was run three separate times with similar results.  
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3.4. Treatment of Andrographis paniculata extracts inhibited ERK phosphorylation and 
promoted caspase 3 cleavage:   
           Caspase 3 activation and inhibition of ERK phosphorylation were examined to determine 
whether Andrographis paniculata extracts inhibited survival signals and induced apoptosis as a 
mechanism of action. B16-BL6 cells were treated with Andrographis paniculata extracts 
(ethanol, aqueous) at varying concentrations. In addition, untreated cells were utilized as a 
negative control while UV-treated cells were used as a positive control for apoptosis. The 
treatment of B16-BL6 cells with the ethanol extract showed caspase-3 cleavage after 24 h of 
treatment (Figure 3.20). The expression of uncleaved caspase 3 bands were prominent at the low 
concentrations but disappeared at the highest concentrations because of cell death and the 
removal of unattached floating cells during the medium removal step. Further, B16-BL6 cells 
that were treated with the ethanol extract of Andrographis paniculata at various concentrations 
promoted a significant inhibition in the phosphorylation of ERK (P-ERK) relative to the ERK1/2 
bands, which allows apoptosis. Clearly, the expression of P-ERK is decreased at the high 
concentrations of extract because of the cell’s death. Furthermore, B16-BL6 cells that were 
treated with various concentrations of the aqueous extract of Andrographis paniculata exhibited 
a very weak band corresponding to caspase-3 cleavage after 24-h treatment (Figure 3.21.). After 
48 h, the B16-Bl6 cells were shown to be undergoing apoptosis by the presence of a strong band 
of caspase-3 cleavage. In addition, the treatment with the aqueous extract showed inhibition of 
PERK compared to the constant expression of ERK1/2.  
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Figure 3.20. The treatment of B16-BL6 cells with the ethanol extract of Andrographis 
paniculata for 24 h promoted caspase-3 cleavage, and inhibited ERK phosphorylation.      
B16-BL6 murine melanoma cells were treated with the ethanol extract of Andrographis 
paniculata at various concentrations for 24h, altered cell survival pathway and induced apoptosis 
by using western blot analysis with three different antibodies: caspase-3, P-ERK and ERK1/2.  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
  
94  
  
A  
   M
ed
ia
 c
on
tr
ol
 
U
V
 c
on
tr
ol
 
1%
 e
th
an
ol
  
0.
1%
 A
. p
an
ic
ul
at
a 
0.
25
%
 A
. p
an
ic
ul
at
a 
0.
50
%
 A
. p
an
ic
ul
at
a 
0.
75
%
 A
. p
an
ic
ul
at
a 
1%
 A
. p
an
ic
ul
at
a 
 
                           
 
 
 
 
 
 
  
  
 
 
 
P-ERK 
 
 
ERK-1/2 
 
 
Caspase-3 
95  
  
 
 Figure 3.21. The treatment of B16-BL6 cells with the aqueous extract of 
Andrographis paniculata promoted caspase-3 cleavage, and inhibited ERK 
phosphorylation.      B16-BL6 murine melanoma cells were treated with the PBS extract 
of Andrographis paniculata at various concentrations for 24 h and 48 h, altered cell 
survival pathway and induced apoptosis by using western blot analysis with three different 
antibodies: caspase-3, P-ERK and ERK1/2.  
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3.5. The effect of Andrographis paniculata extracts on the B16-BL6 cell cycle profile (Sub- 
G1):  
          B16-BL6 cells were treated with a high concentration of the ethanol extract of 
Andrographis paniculata for 24 h.  The results of PI staining showed that 16.63% of the cells 
were apoptotic, in the sub-G1 phase, which represents the percentage of cells with fragmented 
DNA. This percentage increased to 82.09% after 48 h of treatment with the ethanol extract which 
reveals a late stage of apoptosis. This outcome was similar to the UV control, which showed a 
high percentage of apoptotic cells around 86.16%. In contrast, the cells treated with the low dose 
of the ethanol extract showed a small percentage of apoptotic cells (<20%) and a high percentage 
of living cells (Figure 3.22.). It is also interesting to note that cells treated with the low dose of 
the ethanol extract for 24 h, and the high dose of the ethanol extract for 24 h and 48 h also 
showed cells in the S and G2/M phases of the cell cycle.  This indicates that treatment caused 
apoptosis without first blocking the cell cycle. Further, B16-BL6 cells that were treated with the 
aqueous extract of Andrographis paniculata at high dose for 24 h exhibited a lower percentage 
of apoptotic cells of around 6% compare to the UV control (Figure 3.23.). The treatment with the 
aqueous extract for 24 h also showed a regular cell cycle distribution. These findings suggested 
that B16-BL6 cells were more sensitive in response to ethanol extract than aqueous extract. 
Andrographis paniculata induced apoptosis in B16-BL6 cells in a drug concentration-, time- and 
extract type-dependent manner.  
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Figure 3.22. The effect of the ethanol extract of Andrographis paniculata on B16-BL6 cell 
cycle profile (Sub-G1).  
     B16-BL6 murine melanoma cells were treated with the ethanol extract of Andrographis 
paniculata at a low dose for 24 h and at high dose for 24 h and 48 h to measure the DNA content 
of each cell following propidium Iodide staining. The results were analyzed by using a flow 
cytometer and the experiment was run 3 separate times. The graph shows the relative number of 
cells in each phase of the cell cycle (including a sub-G1 population).  
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Figure 3.23. The effect of the aqueous extract of Andrographis paniculata on B16-BL6 cell 
cycle profile (Sub-G1).  
     B16-BL6 murine melanoma cells were treated with the PBS extract of Andrographis 
paniculata at low and high doses for 24 h and the DNA content of each cell was measured using 
propidium iodide staining. The results were analyzed by using flow cytometer and the 
experiment was run 3 separate times.  
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Chapter 4: Discussion  
          Cancer is one of the many progressive disorders known today. Unregulated cellular 
proliferation is the cause of cancer and approximately 6 million new cancer cases are registered 
globally on a yearly basis. The majority of these cases (over 70%) are found among people from 
low- and middle-income countries. According to the world health organization, the potential risk 
factors for cancer include; prolonged tobacco and alcohol consumption, inadequate intake of 
fruits and vegetables, and prolonged infections from some viruses like human papillomavirus 
(HPV), hepatitis C virus (HCV) and hepatitis B virus (HBV). It is estimated that deaths caused 
by cancer will continue to increase globally in the coming years and reach 12 million/year by 
2030 (Butler., 2008). With the rise in cancer incidence, there is an increasing search for natural 
products that may be used as remedies. Such products are already being recognized as effective 
against several disorders. More specifically, natural therapeutic agents have been useful for drug 
discovery in the case of cancer and several infectious diseases (Choudhury& Paddar., 1985; 
Joselin& Jeeva., 2014). For cancer chemotherapy, plant-derived agents including vinblastine, 
paclitaxel, vincristine, epipodophyllotoxin and camptothecin are part of the treatment choices 
that are available for physicians. Nevertheless, the search for new and more efficacious 
therapeutics is a constant endeavor, and a wide variety of flora from all over the world being 
studied to identify potential anticancer agents (Varma, Padh & Shrivastava., 2011).  
          In this regard, a plant called Andrographis paniculata, which has been used for many years 
in Indian and Chinese traditional medicine, has come under focus in recent cancer research. The 
primary bioactive agent derived from this plant is called andrographolide and several research 
studies have shown its anti-tumor activities (Varma, Padh & Shrivastava, 2011). Using in vitro 
studies, we have demonstrated that Andrographis paniculata is capable of inhibiting the growth 
of a variety of cancer cells. Andrographis paniculata is also able to induce apoptosis in B16-BL6 
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mouse melanoma cell line in a time and dose-dependent manner. The following sections will 
discuss our findings, in addition to other studies in detail.  
  
4.1. Anti-proliferative Activity of Andrographis paniculata Extracts:  
         The first study with Andrographis paniculata involved the analysis of an ethanol extract 
and a PBS (aqueous) extract and it ability to inhibit the proliferation of the B16-BL6 murine 
melanoma, ASPC-1 pancreatic cancer, MCF-7 human breast cancer, 4T1 murine breast cancer, 
and MDA-MB-231 human breast cancer cell lines over a period of 5 days by using the MTT 
assay. We found that the ethanol extract showed a significant inhibition of all the cell lines 
across all concentrations. On the other hand, the PBS extract was only effective in stopping cell 
proliferation at the highest concentration, and then only in the B16-BL6, ASPC-1, and MCF-7 
cell lines. There was no inhibition of cell proliferation observed for the 4T1 and MDA-MB-231 
cell lines with the aqueous extract.   
       These findings were in agreement with Suriyo et al., who analyzed the anti-proliferative 
effects of Andrographis paniculata extracts on (HepG2 and SK-Hep1) hepatocellular carcinoma, 
and (HuCCA-1 and RMCCA-1) intrahepatic cholangiocarcinoma cell lines by using the MTT 
assay. An ethanol extract of the first true leaf (FTLEE) and aqueous extract of the mature leaf 
(MLWE) of Andrographis paniculata were applied to these cell lines. They showed that FTLEE, 
which was found to have a high concentration of 14-deoxyandrographolide but low 
andrographolide content in comparison to MLWE, inhibited growth more potently among the 
cancerous hepatic and bile duct cells than its counterpart. While the presence of AP1 in the 
MLWE extract explained its cytotoxic activity against cancer cells, this does not account for the 
difference that was observed in cytotoxicity between the extracts. The authors hypothesized that 
interactions occurring between main active diterpenoids in the extracts, particularly AP1 and 
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AP6, have a role in the compounds’ growth inhibitory effect. The effect of other unknown 
diterpenoids apart from the two on which this study focused could account for the difference in 
cytotoxic potency between FTLEE and MLWE (Suriyo et al., 2014). In addition to the potent 
anti-proliferative effects of Andrographis paniculata extracts (ethanol and aqueous) at different 
growth stages, different cancer cell lines showed variable sensitivity to these extracts. For 
example, Suriyo et al. found that the HuCCA-1 intrahepatic cholangiocarcinoma cell line was 
twice as sensitive to the extracts in comparison to the other cell lines (Suriyo et al., 2014). 
Similarly, our laboratory findings showed that the MCF-7 human breast cancer (triple positive) 
cell line possessed greater sensitivity to the extracts in comparison to the MDA-MB-231 human 
breast cancer (triple negative) and 4T1 mouse breast cancer (triple negative) cell lines. We 
theorize that these differences in the ethanol and aqueous extracts of Andrographis paniculata 
could be due to the differences in the chemical constitutions of these extracts. More specifically, 
we believe that some unknown compounds present in the ethanol (and not the aqueous) extract 
could play an important role in the differences in cell toxicity effects. In addition, we believe that 
the differences in hormone (estrogen) responsiveness between the MCF-7, MDA-MB-231 and 
4T1 cell lines may be responsible for their variable sensitivities to the Andrographis paniculata 
extracts.  
          There are several studies that have been published to study the anti-cancer effect of 
andrographolide, the major active component of Andrographis paniculata, on different cancer 
cell types. In a more recent study, Yang et al., (2010) exposed four different lymphoma cell lines 
(SUDHL4, HF-1, Granta, and Ramos) to 0-100 µmol/L of andrographolide for 2 days. As the 
dosage increased, the rate of cell death also increased and the IC50 (which is defined as the 
concentration of a toxic agent that results in 50% cell death) for two days was noted at 15, 20, 
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30, and 40 µmol/L for HF-1, Ramos, SUDHL4, and Granta cell lines, respectively (Yang et al., 
2010).   
        Furthermore, the anti-proliferative effect of andrographolide has been observed under in 
vivo conditions. Yang et al. injected C6 glioma cells into both ear pinna of ICR mice and allowed 
the cells to grow into tumors for 3 days. At day 3, the tumors on each ear had grown to similar 
sizes. Phosphate buffered saline (negative control) was injected into the left ear and 20 µmol/L of 
andrographolide was injected in the right ear. At day 9, the weight of the tumor in the right ear 
was reduced by 67% suggesting that andrographolide is an effective anti-cancer agent against 
glioma cells (Yang et al., 2014).  
       In summary, these studies present evidence for the anti-tumor effect of Andrographis 
paniculata. This could be attributed to the presence of andrographolide which has been shown to 
possess anti-proliferative properties.  
  
4.2. Apoptosis induction & cell morphological changes by Andrographis paniculata extracts:  
        Apoptosis is a highly regulated process that ensures cellular homeostasis. It is one of the 
hallmarks of cancer treatment and an effective therapeutic response would involve specific 
destruction of cancer cells, and not the neighboring normal cells. Apoptotic cells display a 
specific change in cell morphology and gene expression profiles (Taraphdar, Roy &  
Bhattacharya, 2001). In our study, B16-BL6 cells were treated with varied concentrations of 
Andrographis paniculata extracts for 48 h. The cells were then stained with acridine orange and 
ethidium bromide to determine the morphological changes of the cells using a microscope. These 
dyes are used as indicators of apoptosis. We found that the treatment of B16-BL6 cells with a 
high dose of aqueous extract followed by staining with the dyes caused the presence of bright 
green dots in the nuclei, which was indicative of the fragmentation of the nuclear membrane and 
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condensation of the chromatin. When these cells were treated with a high dose of ethanol extract 
of Andrographis paniculata, the complete destruction of the cells was seen, suggestive of end 
stage apoptosis. These findings were supported by Harjotaruno et al., (2007), who assessed cell 
apoptosis in TD-47 human breast cancer cells by treating them with different concentrations of 
andrographolide and then staining these cells with acridine orange and ethidium bromide. Under 
low doses of andrographolide, the TD-47 cells showed an early-stage of apoptosis with the 
nuclei staining with bright green spots within nuclei. However, under high doses of 
andrographolide, the cells become completely fragmented and incorporated ethidium bromide, 
appearing orange compared to the uniform non-fluorescent appearance of the negative control 
cells (Harjotaruno et al., 2007).  
          Further investigation into the mechanism of action of Andrographis paniculata was done. 
Western blot analysis was used to examine whether Andrographis paniculata extracts are able to 
initiate apoptotic activity by caspase activation and downregulation of the cell survival signal, 
phospho-ERK. Our findings showed that treatment of B16-BL6 with the ethanol extract of 
Andrographis paniculata induced apoptosis by promoting caspase-3 activation and by inhibiting 
phosphorylation of ERK. Additionally, the activity of Andrographis paniculata extracts has been 
shown to be concentration- and time-dependent. When the B16-BL6 cell line was treated with 
the aqueous extract of the plant, we observed that the number of cells that became apoptotic 
increased from 24 to 48 h. Similar findings have been noted by Harjotaruno et al., (2007) which 
described the treatment of TD-47 human breast cancer cells with andrographolide for 24, 48, and 
72 h. The results showed an increase in caspase-3 levels that was associated with a dosage 
dependent increase.   
         Further support for the apoptosis activity of andrographolide was found in Yang et al., 
(2014). In this study, the C6 glioma cell line was exposed to 10, 15, and 20 µM concentrations of 
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andrographolide for 24 and 48 h and the levels of caspase-7 and its downstream target, poly 
(ADP-ribose) polymerase (PARP) were determined. The authors found that treatment with 20 
µM andrographolide for 12 and 24 h caused the levels of caspase-7 to increase by 1.8 and 2.2 
times, respectively. The initial values, were suggestive of inductive effects of andrographolide on 
caspase-7 expression and activation (Yang et al., 2014). Furthermore, they found that the levels 
of cleaved PARP protein were increased 1.5, 3.5, and 3.8 times by treatment for 12, 24, and 48 h, 
respectively. This suggested that andrographolide induced cell death through the caspase-7 – 
PARP signaling pathway, and that activated caspase-7, in turn cleaved and inactivated PARP in a 
dose and time dependent way (Yang et al., 2014).  
          In another study, Yang et al., (2010) analyzed the effect of treating lymphoma cell lines  
(Ramos, Granta, SUDHL4 and HF-1), primary lymphoma patient samples (MCL, DLBCL and 
FL), and normal human lymphocytes with andrographolide for different periods of time and at 
different concentrations. Induction of apoptosis was determined by the activation of caspase-7 
and downstream cleavage of PARP. While andrographolide did not result in significant cell 
death in the normal human lymphocytes, all of the cancer cell lines and patient samples that were 
tested were affected at all doses of the agent and at all periods of time, but to different extents 
(Yang et al., 2010). In addition, the affected cells showed the presence of cleaved PARP and 
activation of other downstream caspases (caspase-8, caspase-9, and caspase-3) in a dosage and 
time dependent way (Yang et al., 2010). Remarkably, this study found that cancer cells from 
patients had a greater sensitivity to andrographolide in comparison to the cancer cell lines, 
suggesting that this agent may have greater anti-cancer potential in clinical trials in comparison 
to in vitro studies (Yang et al., 2010).  
         In summary, our results showed that Andrographis paniculata (33% andrographolide) was 
effective in stimulating apoptosis as measured by caspase 3 activation and P-ERK inhibition.  
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These results were in agreement with earlier studies which revealed and confirmed that 
andrographolide induced apoptosis measured by caspase activation in various cancer cell types.  
  
4.3. Andrographis paniculata and Cell Cycle Analysis:  
         The cell cycle is comprised of four phases, a G1 phase which is variable in duration due to 
the presence of the G0 checkpoint, followed by a synthetic S phase, a G2 phase, and a short 
mitotic M phase, during which the cell grows, doubles its genetic content, and finally divides. 
Controlling the cell cycle in the G1 phase has recently been identified as a potential target for 
cancer treatment and research, since blocking cell division early in the cycle is important in 
developments in cancer treatment. It has been discovered that a large number of the regulatory 
genes associated with the G1 phase have significant effects on differentiation, proliferation, 
apoptosis and oncogenic transformation (Owa et al., 2001). In our study, flow cytometry with 
propidium iodide staining was employed to determine the presence and the changes in cell cycle 
and to assess the number of apoptotic (sub-G1) cells. Upon exposure to the high dose ethanol 
extract for 24 hours, the number of apoptotic cells accumulating in the sub-G1 phase measured 
17%. Prolonged exposure for 48 hours dramatically increased the number of sub-G1 cells to 
82%. This was in contrast to the exposure to high dose of aqueous extract for 24 hours, which 
caused apoptotic changes in only about 6% of the cells. This further reinforced the previous 
finding that the ethanol extract was more potent in inducing apoptosis than the aqueous extract 
and both caused apoptosis in a dose- and time-dependent manner.  
           Suriyo et al. treated the intrahepatic cholangiocarcinoma cell lines (HuCCA-1, RMCCA1) 
with an ethanol extract of the first true leaf of Andrographis paniculata. The cell cycle arrest and 
apoptotic cells were detected by using flow cytometry. It was found that a cell cycle arrest was 
induced in the G0/G1 and the G2/M phases (Suriyo et al., 2014). Furthermore, apoptosis was 
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dose-dependent in both cell lines. Approximately 7.9-37.8% of cells died upon exposure to 
FTLEE at doses from 0.2 mg/mL to 0.8 mg/mL in the HuCCA-1 line and 10.9-50.9% of cells 
died at doses from 0.4 mg/mL to 1.0 mg/mL in the RMCCA-1 cell line (Suriyo et al., 2014). This 
study suggested that Andrographis paniculata extracts stimulate apoptosis and cell cycle arrest in 
the HuCCA-1 and RMCCA-1 cells (Suriyo et al., 2014).  
         Wong et al. subjected human pancreatic cancer, PC-3 cells to 1, 3, 10, and 30 µM 
concentrations of andrographolide for 24 hours and performed flow cytometry to determine the 
cell cycle disruption. It was found that this treatment resulted in PC-3 cells accumulating at the 
G2/M phases and declining in the G1 and S phases (Wong et al., 2011). Interestingly, the authors 
also found that treatment with higher concentrations of andrographolide also caused the 
accumulation of cells in the sub-G1 phase, which indicated the presence of apoptotic cells  
(Wong et al., 2011).  
         In another study, Banerjee et al. determined the cell cycle arrest in the MDA-MB-231 triple 
negative breast cancer cell line following treatment with 30 µM andrographolide for 24, 36, and  
48 h, using flow cytometry analysis. It was found that most cells accumulated in the S phase and 
only a few cells were present in the G1/G0 phase. The number of apoptotic cells increased as the 
duration of andrographolide exposure increased with 41% sub-G1 cells at 48 h (Banerjee et al., 
2016). Other studies have also shown similar findings in hepatoma cells HepG2 (Li et al., 2007), 
colorectal carcinoma, Lovo cells (Shi et al., 2008) and acute myeloid leukemia, HL-60 cells 
(Manikam & Stanslas, 2009; Jayakumar et al., 2013). In summary, our findings were in line with 
the previous studies which indicated that Andrographis paniculata and its major bioactive 
component andrographolide effectively induced cell cycle arrest and apoptosis in variety cancer 
cell lines.  
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5. Conclusion:  
        Cancer is a multi-faceted disorder with several different etiologies and mechanisms for 
pathogenesis. Therefore, there is a constant need for novel therapeutics that could act alone or in 
addition to current remedies. Given the harsh nature of many current cancer therapeutic agents, 
there is a shift towards identifying naturally-derived agents for cancer treatment. In this regard, 
Andrographis paniculata, which is used extensively in South Asian traditional medicine, and has 
been cited in the Ayurveda as having anti-cancer potential, has become a promising agent for 
cancer therapeutic research (Varma et al., 2011). In this study, specific inhibition of cell growth 
and proliferation has been observed in several cancer cell lines, including B16BL6, ASPC-1, 
MCF-7, MDA-MB-231, 4T1 upon exposure to different concentrations and different periods of 
time to Andrographis paniculata extracts. Additionally, it has been determined that the ethanol 
extract is more potent than the aqueous extract in inducing anti- proliferative and apoptotic 
effects. Treatment with Andrographis paniculata extracts induced caspase activation and P-ERK 
inhibition. Further, it has been found that the properties of this agent is dependent on the type of 
extract, and the type of cancer cell lines.   
     However, there is a need for continued research on this agent before it can be proclaimed as a 
cancer therapeutic. In this study, the primary mode of action of Andrographis paniculata extracts 
was apoptosis, while the cell death pathway involved is still unknown. In addition, the dosage 
differences that produce effective cytotoxic responses in animal and human cancer cell lines 
need to be further investigated. Again, Andrographis paniculata has exciting prospects as a 
potent anti-cancer agent, but it needs to be thoroughly investigated before it can be put forward 
as a suitable candidate for cancer drug discovery.  
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